elifeeLifeeLife2050-084XeLife Sciences Publications, Ltd8407010.7554/eLife.84070version of recordResearch ArticleImmunology and InflammationMicrobiology and Infectious DiseaseImmunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class ILeddyOwenhttps://orcid.org/0000-0002-3437-1956123WhiteForest Mhttps://orcid.org/0000-0002-1545-1651134†BrysonBryan Dhttps://orcid.org/0000-0003-1716-6712bryand@mit.edu12†https://ror.org/042nb2s44Department of Biological Engineering, Massachusetts Institute of TechnologyCambridgeUnited Stateshttps://ror.org/002pd6e78Ragon Institute of Massachusetts General Hospital, Harvard, and MITCambridgeUnited StatesKoch Institute for Integrative Cancer ResearchCambridgeUnited StatesCenter for Precision Cancer MedicineCambridgeUnited StatesKanaBavesh DReviewing Editorhttps://ror.org/03rp50x72University of the WitwatersrandSouth AfricaKanaBavesh DSenior Editorhttps://ror.org/03rp50x72University of the WitwatersrandSouth Africa
CD8+ T cell recognition of Mycobacterium tuberculosis (Mtb)-specific peptides presented on major histocompatibility complex class I (MHC-I) contributes to immunity to tuberculosis (TB), but the principles that govern presentation of Mtb antigens on MHC-I are incompletely understood. In this study, mass spectrometry (MS) analysis of the MHC-I repertoire of Mtb-infected primary human macrophages reveals that substrates of Mtb’s type VII secretion systems (T7SS) are overrepresented among Mtb-derived peptides presented on MHC-I. Quantitative, targeted MS shows that ESX-1 activity is required for presentation of Mtb peptides derived from both ESX-1 substrates and ESX-5 substrates on MHC-I, consistent with a model in which proteins secreted by multiple T7SSs access a cytosolic antigen processing pathway via ESX-1-mediated phagosome permeabilization. Chemical inhibition of proteasome activity, lysosomal acidification, or cysteine cathepsin activity did not block presentation of Mtb antigens on MHC-I, suggesting involvement of other proteolytic pathways or redundancy among multiple pathways. Our study identifies Mtb antigens presented on MHC-I that could serve as targets for TB vaccines, and reveals how the activity of multiple T7SSs interacts to contribute to presentation of Mtb antigens on MHC-I.
m. tuberculosisantigen presentationMHC-Isecretion systemsphagosomemacrophagesResearch organismOtherhttp://dx.doi.org/10.13039/100000002National Institutes of HealthR35GM142900-01LeddyOwenhttp://dx.doi.org/10.13039/100000002National Institutes of HealthR01A1022553LeddyOwenhttp://dx.doi.org/10.13039/100000066National Institute of Environmental Health SciencesP42 ES027707LeddyOwenWhiteForest MCenter for Precision Cancer MedicineLeddyOwenWhiteForest Mhttp://dx.doi.org/10.13039/100000002National Institutes of HealthP30 AI06035LeddyOwenThe funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author impact statementHuman macrophages infected with Mycobacterium tuberculosis present peptides derived from substrates of type VII secretion systems on MHC class I via a pathway dependent on the ESX-1 secretion system and independent of antigen processing by the proteasome and cathepsins.Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading cause of infectious disease mortality worldwide, causing approximately 10 million new cases of active TB disease and 1.5 million deaths per year (World Health Organization 2022, 2021). Currently, the only clinically licensed vaccine to prevent TB is Bacille Calmette-Guerin (BCG), which protects children against disseminated Mtb infection (Roy et al., 2014), but provides limited and highly variable protection against pulmonary TB in adults (Fine, 1995). More effective vaccines against TB are therefore needed, but identifying Mtb antigens capable of eliciting protective immunity remains challenging.
Multiple convergent lines of evidence from experiments in mouse and non-human primate models of TB show that CD8+ T cells can contribute to immune control of Mtb infection (Chen et al., 2009; Flynn et al., 1992; Woodworth et al., 2008b), but the antigenic targets of protective CD8+ T cell immunity to Mtb infection have not been conclusively defined. In murine models, CD8+ T cells specific for some immunodominant Mtb antigens poorly recognize Mtb-infected macrophages (Yang et al., 2018), implying that infected macrophages may not present all Mtb antigens that elicit cytokine-producing CD8+ T cell responses (Kamath et al., 2004; Lewinsohn et al., 2017). These results suggest a need to directly identify which Mtb antigens are presented on MHC-I by infected phagocytes (Flynn et al., 2011).
It is currently unknown which Mtb proteins are able to enter MHC-I antigen processing pathways in macrophages infected with virulent Mtb. Whereas some bacterial species are lysed following phagocytosis and expose their internal cell contents to antigen processing pathways (Shen et al., 1998), a high proportion of virulent Mtb remains intact and viable in macrophages (Armstrong and Hart, 1975; Lee et al., 2008; Lewis et al., 2003), leading us to hypothesize that only a subset of Mtb proteins may be accessible for processing and presentation on MHC-I. Here, we use MS-based identification of peptides bound to MHC-I (immunopeptidomics) to directly identify Mtb-derived peptides presented on MHC-I in primary human macrophages infected with virulent Mtb H37Rv, revealing potential targets for CD8+ T cell-mediated immunity. Additionally, we use targeted MS to quantify changes in the presentation of Mtb peptides resulting from genetic perturbations to Mtb and chemical perturbations to the host cell, allowing us to probe host and bacterial determinants of antigen presentation on MHC-I in Mtb infection.
Results
To identify Mtb antigens presented on MHC-I, we infected primary human monocyte-derived macrophages with Mtb H37Rv, isolated MHC-I by immunoprecipitation 72 hours post-infection, purified the associated peptides, and identified peptides by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). We selected the 72 hour time point over shorter time points to allow sufficient time for antigen processing and presentation on MHC-I. Past experience suggested that choosing a longer time point would have resulted in a high rate of cell death. For an initial set of three analyses, we adapted a previously described protocol (Stopfer et al., 2020; Protocol 1 – see Methods) for use in a biosafety level 3 (BL3) setting. We developed a further optimized protocol (Protocol 2 – see Methods) that we used for 3 additional analyses (Figure 1A). The class I human leukocyte antigen (HLA) genotypes of the 6 donors analyzed were largely distinct from one another (Table 1), enabling us to identify peptides associated with a variety of HLA alleles.
The MHC-I immunopeptidome of <italic>Mtb</italic>-infected human macrophages is enriched for T7SS substrates.
(A) Schematic representation of two immunopeptidomics workflows used to profile the MHC-I repertoire of Mtb-infected primary human macrophages. IP: immunoprecipitation. MWCO: molecular weight cutoff. LC-MS/MS: liquid chromatography coupled to tandem mass spectrometry. (B) Absolute and relative number of Mtb-derived MHC-I peptides identified for each donor. Macrophages from donor B were pre-treated for 24 hr with 10 ng/mL IFN-γ, and macrophages from donor C were treated with 0.5 µg/mL cycloheximide (CHX) for the final 6 hr of infection. (C) Sequences, source proteins, associated HLA alleles, and donors for each validated Mtb-derived MHC-I peptide. (D) Enrichment analysis of Mtb peptides presented on MHC-I and their source proteins, categorized by protein secretion pathway using SignalP 6.0 (Teufel et al., 2022) and a curated set of known or strongly suspected T7SS substrates. p-Values for enrichment analyses of proteins and peptides were determined using the binomial test and the hypergeometric test respectively (see Methods).
Source data for enrichment analysis.
Performance of two BSL-3 compatible MHC-I immunopeptidomics workflows.
(A) Length distribution of MHC-I peptides identified by MS for protocol 1 and protocol 2 (see Figure 1A and Methods), for all detected peptides and validated Mtb-derived peptides. (B) Predicted hydrophobicity index (computed using the ProtViz R package; https://rdrr.io/cran/protViz/man/ssrc.html) as a function of retention time for protocols 1 and 2. Green points indicate validated Mtb peptides. (C) Absolute Mtb protein abundance in axenic culture as a function of protein rank, as quantified by Schubert et al., 2015. Red points indicate source proteins of peptides detected in the MHC-I repertoire of Mtb-infected macrophages (see Figure 1c).
Gibbs clustering groups MHC-I peptides into clusters that correspond to HLA alleles expressed by each donor.
Heatmap of peptide binding score predicted by NetMHCpan 4.1, Gibbs clustering motif, and corresponding published binding motif for each HLA allele expressed by (A) donor B, (B) donor C, (C) donor D, (D) donor E, (E) donor F.
Predicted class I HLA binding of <italic>Mtb</italic>-derived MHC-I peptides.
Heatmap of peptide binding score predicted by NetMHCpan 4.1 for Mtb-derived peptides for each HLA allele expressed by (A) donor B, (B) donor C, (C) donor D, (D) donor E, (E) donor F. Label colors correspond to the clusters defined by Gibbs clustering of the full set of identified peptides (see Figure 1—figure supplement 2).
Workflow for validating <italic>Mtb</italic>-derived MHC-I peptide identifications by SureQuant.
Schematic showing how MHC-I peptide samples were divided between DDA-based discovery analyses (75%) and SureQuant-based validation analyses (25%). MS/MS spectra from survey analyses of mixtures of SIL peptide standards alone were compared to the MS/MS spectra of the corresponding biological peptides. Chromatograms demonstrating co-elution of biological peptides with the corresponding SIL standards were obtained by SureQuant.
Validation of <italic>Mtb</italic>-derived MHC-I peptide identifications (VYLTAHNAL, EAVQDVARTY, EVHSAMLNY, AEILRGVSA).
Representative MS/MS spectrum comparisons (left) and SureQuant product ion chromatograms for Mtb-infected and mock-infected macrophages (right column) for each peptide. For each peptide, the amino acid that is stable isotope labeled in the synthetic standard is indicated in red.
Validation of <italic>Mtb</italic>-derived MHC-I peptide identifications (AEHGMPGVP, LPFEDAPLI, AAWGGSGSEAY, ELDEISTNIRQAGVQY).
Representative MS/MS spectrum comparisons (left) and SureQuant product ion chromatograms for Mtb-infected and mock-infected macrophages (right column) for each peptide. For each peptide, the amino acid that is stable isotope labeled in the synthetic standard is indicated in red.
Validation of <italic>Mtb</italic>-derived MHC-I peptide identifications (IDHQFVATL, NASPVAQSY, VPLEGGGRL, TQHDAADALF).
Representative MS/MS spectrum comparisons (left) and SureQuant product ion chromatograms for Mtb-infected and mock-infected macrophages (right column) for each peptide. For each peptide, the amino acid that is stable isotope labeled in the synthetic standard is indicated in red.
Validation of <italic>Mtb</italic>-derived MHC-I peptide identifications (SEAYQGVQQKW, QEQASQQIL, LLDEGKQSL, QTVEDEARRMW).
Representative MS/MS spectrum comparisons (left column) and SureQuant product ion chromatograms for Mtb-infected and mock-infected macrophages (right column) for each peptide. For each peptide, the amino acid that is stable isotope labeled in the synthetic standard is indicated in red.
Class I HLA alleles expressed by primary monocyte donors.
Donor
HLA-A allele 1
HLA-A allele 2
HLA-B allele 1
HLA-B allele 2
HLA-C allele 1
HLA-C allele 2
A
ND
ND
ND
ND
ND
ND
B
02:01
24:02
07:02
27:07
07:02
15:02
C
01:01
02:01
44:03
57:01
06:02
16:01
D
23:01
26:01
35:01
50:01
04:01
06:02
E
11:01
24:02
39:06
51:01
07:02
15:02
F
01:01
26:01
35:01
38:01
04:01
12:03
We identified thousands of peptides for each primary cell donor, with a length distribution typical of MHC-I peptides (Figure 1—figure supplement 1A) and retention times that correlated well with hydrophobicity (Figure 1—figure supplement 1B). Unsupervised clustering of identified peptides using GibbsCluster 2.0 (Andreatta et al., 2017) revealed groups corresponding to the known peptide sequence binding motifs of class I HLA alleles expressed by each donor (Figure 1—figure supplement 2), confirming the specificity of our pulldowns. Mtb-derived MHC-I peptides detected in each pulldown were predicted to bind at least one class I HLA allele expressed by the donor (Figure 1—figure supplement 3). Mtb peptides made up less than 0.1% of MHC-I peptides identified, and this proportion was not discernibly increased by pre-treating macrophages with IFN-γ or treating with cycloheximide to inhibit host protein synthesis (Figure 1B).
Putative Mtb peptides that passed manual inspection of MS/MS spectra and extracted ion chromatograms (see Methods) were further validated using internal standard parallel reaction monitoring (IS-PRM, also known as SureQuant) (Gallien et al., 2015; Stopfer et al., 2021a; Figure 1—figure supplement 4). Putative Mtb peptides that had MS/MS spectra that closely matched that of a synthetic stable isotope-labeled (SIL) standard, co-eluted with the SIL standard, and were not detected in mock-infected control samples by SureQuant were considered correctly identified, authentic Mtb peptides (Figure 1—figure supplement 5). 77.85% of MASCOT identifications of putative Mtb peptides were rejected after manual data inspection, and of the remaining candidates a further 51.51% were rejected following analysis by SureQuant (Table 2), highlighting the need for rigorous validation using best practices (Fritsche et al., 2021) when identifying pathogen-derived peptides among an MHC repertoire dominated by host-derived peptides.
Putative <italic>Mtb</italic>-derived peptides that passed manual inspection of DDA MS data but failed SureQuant validation.
Source protein
Peptide sequence
Rv0383c
AAPGRPVAPG
pyrD
GDRLALISV
Rv2303c
KHPNVYLEL
Rv0839
YTHGYHES
kgd
AERAAAAAP
Rv1375
EAAQSRITA
GabD1
AKVGASAAY
PE1
AAGNLRAAI
HlfX
IPYDRGDLV
Rv2807
AKWILEGIK
Rv3818
IAPELVRT
Rv1065
YTRIHGDEEL
Rv0293c
DELIAGLAY
Rv3779
VAIAVGPALT
PPE55
TVAPINLNP
Rv2263
QEIEEGIL
Rv0333
GEDPGIAR
Of the 16 Mtb-derived MHC-I peptides we identified, 13 (81.25%) derived from proteins secreted via type VII secretion systems (T7SS) (Figure 1C). The Mtb genome encodes five of these protein export machines (designated ESX-1, 2, 3, 4, and 5; Abdallah et al., 2007), and we identified MHC-I peptides derived from proteins known to be secreted by three of these systems [ESX-1 (Guinn et al., 2004; Millington et al., 2011; Stanley et al., 2003), ESX-3 (Siegrist et al., 2009; Tufariello et al., 2016), and ESX-5 (Abdallah et al., 2006; Daleke et al., 2012; Ekiert and Cox, 2014; Shah et al., 2015)]. For several T7SS substrates, we identified multiple peptides from the same protein, and/or identified the same peptide across multiple donors. These antigens included EsxA, PPE20, EspC, and PE35, as well as sequences conserved among the four nearly identical members of the EsxJ family of proteins (EsxJ, EsxK, EsxP, and EsxW – referred to here as EsxJKPW). T7SS substrates were significantly overrepresented in the MHC-I repertoire relative to the whole Mtb proteome, both at the peptide level (p<10–10; binomial test with Bonferroni correction) and at the protein level (p<10–7; hypergeometric test with Bonferroni correction; Figure 1D). Proteins without identifiable secretion signals were significantly underrepresented among Mtb-derived MHC-I peptides (p<10–8; binomial test with Bonferroni correction) and source proteins (p<10–6; hypergeometric test with Bonferroni correction). While some of the Mtb antigens we identified are highly abundant compared to the rest of the Mtb proteome (e.g. EsxB), the abundances of other T7SS substrates are near the mean (Figure 1—figure supplement 1C; Schubert et al., 2015), suggesting that the overrepresentation of T7SS substrates is not solely due to greater abundance relative to the rest of the Mtb proteome. These results suggest that T7SS substrates may preferentially gain access to MHC-I antigen processing pathways.
To nominate possible mechanisms by which Mtb antigens might be processed and loaded onto MHC-I, we used confocal microscopy to examine the intracellular fate of Mtb in primary human macrophages. We hypothesized that Mtb antigens could either (1) be processed by endolysosomal proteases and loaded onto MHC-I in Mtb-containing compartments, or (2) gain access to cytosolic antigen processing pathways via permeabilization of the phagosome membrane (Grotzke et al., 2010; Grotzke et al., 2009; van der Wel et al., 2007; Figure 2A). In a subset of macrophages at both early and late timepoints, a subset of Mtb co-localized with Galectin-3, a marker of phagosomal membrane permeabilization (Chauhan et al., 2016; Watson et al., 2012; Figure 2B–C; Figure 2—figure supplement 1A). A subset of Mtb also co-localized with P62, an autophagy adaptor protein that recognizes cytosol-exposed bacteria (Watson et al., 2012; Zheng et al., 2009; Figure 2B–C; Figure 2—figure supplement 1B). Since bacteria become ubiquitinated upon exposure to the cytosol and recruitment of autophagy adaptor proteins to the Mtb phagosome has previously been associated with damage to the phagosomal membrane (Watson et al., 2012), these results suggest that Mtb gains access to the host cytosol in primary human macrophages, as has previously been shown in murine macrophages (Mittal et al., 2018) and in cell lines (Beckwith et al., 2020). A subset of Mtb-containing phagosomes co-localized with the late endosome and lysosome marker LAMP-1 (Figure 2B–C; Figure 2—figure supplement 1C), suggesting access to endolysosomal proteases, but Mtb-containing phagosomes did not co-localize with MHC-I itself (Figure 2B–C; Figure 2—figure supplement 1D), suggesting that Mtb antigens were unlikely to be loaded onto MHC-I in the Mtb-containing phagosome. These results suggested that access to the host cell cytosol represented a likely route for processing and presentation of Mtb antigens. An Mtb strain deficient in the activity of the ESX-1 secretion system (eccCa1:Tn) exhibited reduced co-localization with Galectin-3 and P62 (Figure 2D–F). Our results are consistent with prior studies demonstrating that ESX-1 activity is required for Mtb to damage the phagosome membrane (Augenstreich et al., 2017; Simeone et al., 2012; Watson et al., 2012) and show that this phenomenon occurs in our primary human macrophage infection model.
<italic>Mtb</italic> co-localizes with markers of phagosome membrane damage in an ESX-1-dependent manner and does not co-localize with MHC-I.
Primary human macrophages were infected with GFP-expressing wild-type Mtb, fixed at 24, 72, or 120 hr post-infection, stained by immunofluorescence (IF), and imaged by spinning-disk confocal microscopy. (A) Schematic showing markers associated with each of two possible pathways of Mtb antigen processing and presentation. (B) Representative images of Mtb-infected macrophages stained for Galectin-3, P62, MHC-I, or LAMP-1. Scale bar indicates 10 µm. White arrows indicate Mtb-containing phagosomes co-localizing with each marker. (C) Automated quantification (see Methods) of the proportion of co-localized Mtb-containing phagosomes for each marker for n=4 donors (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001; one-way ANOVA with Tukey’s multiple comparisons test). (D) Representative images of macrophages infected with wild-type (H37Rv) or ESX-1-deficient (eccCa1:Tn) Mtb stained for Galectin-3 or P62. Scale bar indicates 10 µm. White arrows indicate Mtb-containing phagosomes co-localizing with each marker. (E–F) Automated quantification of the relative proportion of GFP +objects co-localized with IF staining for Galectin-3 (E) or P62 (F) as a function of time post-infection for n=3 donors, normalized to wild-type (H37Rv) (* p<0.05, ** p<0.01, *** p<0.001; paired t-test). Error bars indicate standard deviation.
Single-channel images.
Colocalization quantification source data.
Immunofluorescence staining for Galectin-3, P62, LAMP-1, and MHC-I is specific.
Representative spinning disk confocal microscopy images comparing macrophages stained with primary antibody specific for galectin-3 (A), P62 (B), LAMP-1 (C), or MHC-I (D) to those stained with secondary antibody alone, 120 hr post-infection.
Our microscopy results led us to hypothesize that ESX-1-mediated phagosomal membrane damage might be required for Mtb antigens to access MHC-I antigen processing pathways (Figure 3A). If this were the case, ESX-1 activity would be required for presentation not only of peptides derived from ESX-1 substrates (e.g. EsxA28-36 – sequence LLDEGKQSL), but also peptides derived from substrates of other T7SSs (e.g. EsxJKPW24-34 – sequence QTVEDEARRMW – which is derived from ESX-5 substrates that do not require ESX-1 for secretion; Champion et al., 2006). To test this hypothesis, we turned to quantitative targeted MS (SureQuant) to quantify changes in the presentation of EsxA28-36 and EsxJKPW24-34 across multiple experimental conditions (Figure 3B). We used primary macrophages from donors expressing HLA-A*02:01 and HLA-B*57:01 for these experiments to ensure presentation of the target peptides. Because the other Mtb epitopes detected in our untargeted MS experiments are not expected to bind these HLA alleles, we only targeted EsxA28-36 and EsxJKPW24-34. While this targeted approach is limited in the number of epitopes it can detect, it enables reliable and accurate quantification of peptides across experimental conditions with low sample input. Because methionine residues of peptides can oxidize during sample handling, we targeted both the oxidized and non-oxidized form of EsxJKPW24-34 where possible. In addition to the SIL synthetic trigger peptides required for SureQuant, we also spiked pre-formed heavy isotope labeled peptide-MHC complexes (hipMHCs) into the lysates prior to immunoprecipitation to provide an internal standard that can be used to normalize out technical variation, which improves the accuracy of label-free quantification (Stopfer et al., 2020).
ESX-1 activity is required for presentation of EsxA<sub>28-36</sub> and EsxJKPW<sub>24-34</sub> on MHC-I, independently of type I interferon signaling.
(A) Schematic representation of the localization of EsxA and EsxJKPW in macrophages infected with wild-type Mtb H37Rv or the ESX-1-deficient eccCa1:Tn transposon mutant. (B) Schematic showing our workflow for targeted detection and quantification of Mtb-derived MHC-I peptides by SureQuant, using stable isotope labeled peptide-MHC complexes (hipMHCs) as internal standards. SIL: stable isotope labeled. (C) Relative quantification of EsxA28-36 and EsxJKPW24-34 by SureQuant in macrophages infected with no Mtb (mock), wild-type Mtb H37Rv, or eccCa1:Tn for n=3 donors (all HLA-A*02:01+, HLA-B*57:01+). As oxidation of methionine is common during sample handling, both the oxidized and non-oxidized form of EsxJKPW24-34 were quantified. (D) Luminescence as a function of time measured for macrophages infected with luciferase-expressing Mtb, in a wild-type H37Rv or eccCa1:Tn background, with or without the addition of 10 ng/mL IFN-β in the culture media. Addition of 25 µg/mL rifampicin (RIF) to the culture media was used as a control showing reduced luminescence with bacterial death. Data points and error bars represent the mean and standard deviation of n=3 donors, each of which represents the mean of three technical replicates. (* p<0.05, one-way ANOVA with Dunnett’s multiple comparisons test, relative to H37Rv as the reference condition). (E) CXCL10 concentration in the culture media 72 hr post-infection quantified by ELISA. Data points each represent the mean of three technical replicates for a given donor. (* p<0.05, ** p<0.01, one-way ANOVA with Tukey’s multiple comparisons test on log-transformed concentrations.) (f) Relative quantification of EsxA28-36 and EsxJKPW24-34 by SureQuant in macrophages infected with no Mtb (mock), wild-type Mtb H37Rv, or eccCa1:Tn for n=3 donors (all HLA-A*02:01+, HLA-B*57:01+). (**** p<0.001, one-way ANOVA with Tukey’s multiple comparisons test.). Error bars indicate standard deviation.
Relative abundances of <italic>Mtb</italic>-derived MHC-I peptides determined by SureQuant.
CXCL10 ELISA raw data.
Infection of macrophages with wild-type or ESX-1-deficient <italic>Mtb</italic> strains results in similar rates of infection and does not affect surface MHC-I levels 72 hr post-infection.
Macrophages infected with GFP-expressing wild-type (H37Rv) or ESX-1-deficient (eccCa1:Tn) Mtb were surface stained for MHC-I 72 hr post-infection and analyzed by flow cytometry. (A) Representative contour plots of GFP fluorescence intensity vs. autofluorescence, showing gating for GFP +infected cells. (B) Proportion of GFP + cells for n=3 donors (** p<0.01, *** p<0.001; one-way ANOVA with Tukey’s multiple comparisons test). (C) Representative histograms of surface MHC-I fluorescence intensity. (D) Mean MHC-I fluorescence intensity (MFI) for n=3 donors (p-values determined by one-way ANOVA with Tukey’s multiple comparisons test). Error bars indicate standard deviation.
Source data for plots.
Targeted MS analysis revealed that macrophages infected with ESX-1-deficient Mtb (eccCa1:Tn) did not present either EsxA28-36 or EsxJKPW24-34 on MHC-I (Figure 3c). We assessed alternative explanations for this difference in presentation of EsxA28-36 and EsxJKPW24-34 and observed no difference in Mtb outgrowth (Figure 3D), the proportion of cells infected (Figure 3—figure supplement 1A–B), or total MHC-I surface expression (Figure 3—figure supplement 1C–D) between macrophages infected with wild-type or ESX-1-deficient Mtb. These results show that ESX-1 activity is required for presentation of EsxA28-36 and EsxJKPW24-34 on MHC-I in macrophages.
To determine whether the absence of EsxA28-36 and EsxJKPW24-34 in the MHC-I repertoire of macrophages infected with ESX-1-deficient Mtb could be attributed to a loss of type I interferon signaling (Stanley et al., 2007), we added exogenous IFN-β to macrophages infected with ESX-1-deficient Mtb and again quantified presentation of EsxA28-36 and EsxJKPW24-34 by SureQuant. Addition of exogenous IFN-β restored a type I interferon response as measured by production of CXCL10 (Figure 3E), but did not rescue presentation of EsxA28-36 or EsxJKPW24-34 on MHC-I (Figure 3F). These results show that presentation of EsxA28-36 or EsxJKPW24-34 on MHC-I is dependent on ESX-1 activity but independent of downstream type I interferon signaling, consistent with a model in which ESX-1-mediated phagosomal damage enables Mtb antigens to access MHC-I antigen processing pathways.
Many MHC-I peptides are proteolytically processed by the proteasome (Kloetzel, 2001), while others are processed by endosomal or lysosomal proteases (Grotzke et al., 2017; Shen et al., 2004). To determine whether these mechanisms contribute to presentation of Mtb peptides on MHC-I, we treated HLA-A*02:01+, HLA-B*57:01+ macrophages with inhibitors of proteasome activity (MG-132), cysteine cathepsin activity (E64d), and lysosomal acidification (bafilomycin; Figure 4A). We quantified presentation of EsxA28-36 and EsxJKPW24-34 on MHC-I along with five host-derived HLA-A*02:01-binding peptides identified in previous studies (Stopfer et al., 2021b) that could be reliably detected in the MHC-I repertoire of macrophages. We began drug treatment of the macrophages prior to infection with Mtb and limited the duration of infection to 24 hr so that the cells could be treated with drug for the full duration of the infection without excessive cytotoxicity (Figure 4B). Treatment with MG-132 inhibited proteasome activity, as measured by accumulation of proteins modified with K48-linked polyubiquitin (Figure 4—figure supplement 1A–B). Treatment with E64d inhibited cathepsin B activity, as measured by a fluorometric assay (Figure 4—figure supplement 1C). Treatment with bafilomycin inhibited lysosomal acidification, as measured by lysotracker staining (Figure 4—figure supplement 1D–E). All three drugs exhibited minimal cytotoxicity in macrophages at the doses used in our immunopeptidomic experiments (Figure 4—figure supplement 2), did not inhibit phagocytosis of Mtb or bacterial outgrowth (Figure 4—figure supplement 3), and did not have a significant effect on surface MHC-I levels (Figure 4—figure supplement 3).
Inhibition of conventional antigen processing proteolytic pathways does not impair presentation of EsxA<sub>28-36</sub> and EsxJKPW<sub>24-34</sub> on MHC-I.
(A) Schematic representation of proteolytic pathways inhibited by the proteasome inhibitor MG-132, the V-type ATPase inhibitor bafilomycin, and the cysteine cathepsin inhibitor E64d. (B) Schematic showing the timing of drug treatment and Mtb infection for targeted MS experiments. (C) Heatmap showing relative abundance of self and Mtb-derived MHC-I peptides determined by SureQuant in mock-infected macrophages or Mtb-infected macrophages treated with MG-132, bafilomycin, E64d, or DMSO-only control. Colors represent the mean fold change relative to the DMSO-treated, Mtb-infected condition for n=3 donors (all HLA-A*02:01+, HLA-B*57:01+). (D–E) Relative abundance of EsxA28-36 (D) and EsxJKPW24-34 (E) determined by SureQuant in mock-infected macrophages or Mtb-infected macrophages treated with MG-132, bafilomycin, E64d, or DMSO-only control for n=3 donors (all HLA-A*02:01+, HLA-B*57:01+). Error bars indicate standard deviation.
Relative abundances of MHC-I peptides determined by SureQuant.
MG-132, E64d, and bafilomycin effectively inhibit their targets in <italic>Mtb</italic>-infected macrophages.
Where applicable, red arrows indicate the dose of each drug used in MS experiments. (A–B) Representative western blots for K48-linked polyubiquitinated protein in uninfected (A) or Mtb-infected (B) macrophages. β-actin is included as a loading control. (C) Quantification of K48-polyubiquitinated protein by densitometry of western blots for n=3 donors. Values are normalized to the abundance of β-actin, also quantified by densitometry of western blots. EC50 was determined by fitting a curve of the form 100% × [MG-132]/([MG-132]+EC50). Data points and error bars represent the mean ± standard deviation. (D) Relative cathepsin B activity (as measured via hydrolysis of the fluorogenic cathepsin B substrate Z-RR-AMC; see Methods) as a function of E64d concentration in mock-infected and Mtb-infected macrophages. EC50 was determined by fitting a curve of the form 100% × [1 - [E64d]/([E64d]+EC50)]. Data points and error bars represent the mean ± standard deviation. (E) Representative spinning disk confocal microscopy images of mock-infected or Mtb-infected macrophages treated with 10 nM bafilomycin for 24 hr and stained with lysotracker red. (F) Mean lysotracker-positive area per cell for n=3 donors. (* p<0.05, *** p<0.001; paired one-tailed T-test). Error bars indicate standard deviation.
Uncropped western blot images.
Source data for plots.
MG-132, E64d, and bafilomycin have minimal cytotoxicity at effective doses in <italic>Mtb</italic>-infected macrophages.
Mock-infected or Mtb-infected macrophages were treated with each drug at the indicated concentrations, and the change in cell viability was measured by lactate dehydrogenase (LDH) release assay. Where applicable, red arrows indicate the dose of each drug used in MS experiments. Data points and error bars represent the mean ± standard deviation. (A) MG-132 (n=4 donors), (B) bafilomycin (10 nM; n=4 donors), (C) E64d (n=3 donors).
Source data for plots.
Treatment of macrophages with MG-132, E64d, and bafilomycin does not impair phagocytosis or outgrowth of <italic>Mtb</italic>.
Macrophages were pre-treated with media containing drug or vehicle control for 1 hr and infected with Mtb in media containing drug or vehicle control, as in MS experiments. (A) Representative flow cytometry contour plots of GFP fluorescence vs. autofluorescence in macrophages infected with GFP-expressing Mtb, immediately after being allowed to phagocytose Mtb for 4 hr at an MOI of 2.5. (B) Quantification of the proportion of macrophages that took up Mtb (i.e. were GFP+) (p-values determined by one-way ANOVA with Dunnett’s multiple comparisons test). (C) Luminescence as a function of time post-infection for macrophages infected with Mtb expressing a luciferase reporter. Rifampicin (RIF) is included as a control demonstrating inhibition of growth. Datapoints and error bars represent the mean ± standard deviation for n=3 donors, each representing the mean of three technical replicates. (D) Representative flow cytometry plot of MHC-I surface expression in macrophages infected with Mtb (or mock-infected) and treated with MG-132, E64d, bafilomycin, or DMSO alone for 24 hr. (E) Quantification of surface MHC-I mean fluorescence intensity (MFI) (p-values determined by one-way ANOVA with Dunnett’s multiple comparisons test).
Source data for plots.
Treatment of macrophages with E64d and bafilomycin does not significantly reduce surface levels of MHC-II.
Macrophages were pre-treated with media containing drug or vehicle control for 1 hr and infected with Mtb in media containing drug or vehicle control, as in MS experiments. (A) Representative flow cytometry contour plots of HLA-DQ and HLA-DR surface staining in macrophages infected with Mtb (or mock-infected), 24 hr post-infection, treated with E64d, bafilomycin, or DMSO alone. (B–C) Quantification of mean fluorescent intensity (MFI) of surface HLA-DR (B) and HLA-DQ (C) staining in Mtb-infected macrophages for n=3 donors (p-values determined by one-way ANOVA with Dunnett’s multiple comparisons test).
Source data for plots.
Treatment with MG-132 and E64d each respectively reduced presentation of a subset of self MHC-I peptides but did not reduce presentation of Mtb peptides (Figure 4C). Treatment with bafilomycin broadly increased presentation of target MHC-I peptides (Figure 4C). This increase was statistically significant for EsxA28-36 (Figure 4D; p<0.05, one-way ANOVA with Dunnett’s multiple comparisons test), though not for EsxJKPW24-34 (Figure 4E). Cell surface levels of HLA-DR and HLA-DQ were not significantly affected by bafilomycin or E64d treatment (Figure 4—figure supplement 4), suggesting that E64d and bafilomycin did not substantially stall MHC-II antigen presentation and their effects of on MHC-I presentation could not be explained as indirect effects of modulating antigen entry into the MHC-II antigen processing pathway. Our results suggest that processing of Mtb peptides for presentation on MHC-I relies on antigen processing proteases other than the proteasome, cysteine cathepsins, or other acidification-dependent lysosomal proteases, and/or that multiple redundant pathways contribute to processing of Mtb peptides for presentation on MHC-I.
Discussion
Our analysis of the MHC-I repertoire of primary human macrophages infected with Mtb revealed that T7SS substrates are a prominent source of Mtb peptides presented on MHC-I. Our findings contrast with those of previous studies of the immunopeptidome of macrophage cell lines infected with BCG (Bettencourt et al., 2020) and the avirulent strain Mtb H37Ra (Flyer et al., 2002), in which the mycobacterial peptides identified included twin arginine translocation (Tat) pathway substates, Sec pathway secretion substrates, membrane-associated proteins, and cytosolic proteins, with no apparent enrichment for T7SS substrates. Given that we showed ESX-1 activity contributes to presentation of Mtb antigens in infection with virulent Mtb H37Rv, the fact that BCG and Mtb H37Ra are both deficient in ESX-1 activity (Frigui et al., 2008; Gordon et al., 1999; Guinn et al., 2004; Lewis et al., 2003; Pym et al., 2002) may in part explain this difference in the mycobacterial peptides presented on MHC-I. The absence of ESX-1 in BCG therefore could limit the ability of BCG to prime effective T cell responses against Mtb, not only because of the absence of antigens encoded in the ESX-1 locus but also because of altered or reduced presentation of other antigens (Pym et al., 2003).
Our findings contrast with previous work arguing that ESX-1 activity is dispensable for presentation of Mtb antigens on MHC-I (Lewinsohn et al., 2006; Woodworth et al., 2008a). ESX-1 activity is not required for Mtb-infected human monocyte-derived dendritic cells to present an epitope derived from TB8.4 (a Sec pathway substrate) to cognate T cells (Lewinsohn et al., 2006). While ESX-1 activity is required for priming of CD8+ T cell responses specific for EsxB in vivo in mice, it is dispensable for priming of CD8+ T cell responses specific for antigens exported via other secretion systems (such as TB8.4 and EsxH) (Woodworth et al., 2008b). While these prior results suggest that the requirements for presentation of Mtb antigens on MHC-I may vary among Mtb antigens and/or vary among antigen presenting cell types, our results show that ESX-1 activity is essential for the presentation of certain Mtb antigens in infected human macrophages, beyond ESX-1 substrates alone. Whereas in axenic culture, secretion of ESX-5 substrates is independent of ESX-1 function (Champion et al., 2006; Shah and Briken, 2016), the fact that presentation of peptides derived from an ESX-5 substrate on MHC-I requires ESX-1 activity supports the hypothesis that the localization of secreted Mtb proteins within a host cell may depend on the activity of multiple T7SSs. This dependence on multiple T7SSs has previously been shown for other ESX-5 substrates such as CpnT (Izquierdo Lafuente et al., 2021), and a functional interdependence between ESX-1 and ESX-3 (which respectively damage the phagosome membrane and prevent host membrane repair) has previously been proposed (Mittal et al., 2018). Our results suggest that the interdependence of Mtb T7SSs in an intracellular context influences the availability of Mtb antigens for processing and presentation on MHC-I.
Prior studies have shown that Mtb antigens must access the cytosol to be presented on MHC-I in human monocyte-derived dendritic cells (Grotzke et al., 2010; Grotzke et al., 2009; Lewinsohn et al., 2006), and our results are consistent with a model in which ESX-1-mediated phagosomal membrane damage enables Mtb antigens to access cytosolic antigen processing and presentation pathways. However, further evidence will be needed to establish whether phagosomal membrane damage alone is sufficient to enable presentation of Mtb antigens on MHC-I in the absence of other ESX-1 functions. Given that our quantitative MS experiments only targeted two Mtb-derived epitopes, further experiments will also be needed to determine whether these results extend to all Mtb T7SS substrates or all Mtb MHC-I antigens, or only a subset.
In this study, we used strain H37Rv for the sake of consistency with other prior studies on antigen presentation on MHC-I and phagosome membrane damage in Mtb-infection, but antigen presentation may vary among Mtb isolates. Mtb isolates have been shown to differ in their level of ESX-1 activity (Solans et al., 2014), as well as carrying mutations in Esx-family proteins and other T7SS substrates (Saelens et al., 2022; Uplekar et al., 2011). Further studies across multiple isolates may therefore reveal differences in antigen presentation that could be relevant for the design of broadly protective vaccines.
We showed that presentation of two Mtb-derived peptides on MHC-I was independent of the activity of proteases commonly associated with antigen processing (the proteasome and cysteine cathepsins), suggesting an alternate processing mechanism. Other proteases have previously been proposed to contribute to proteolytic processing of antigens for presentation on MHCs, including tripeptidyl peptidase II (Geier et al., 1999; Guil et al., 2006; Lázaro et al., 2015; York et al., 2006), nardilysin (Kessler et al., 2011), thimet oligopeptidase (Kessler et al., 2011), metalloproteinases (Lorente et al., 2012), and serine cathepsins such as Cathepsin G that are not inhibited by E64d (Burster et al., 2010). Some of these or other enzymes may be responsible for proteolytic processing of EsxA28-36 and EsxJKPW24-34, or may have a redundant role that can compensate for inhibition of conventional antigen processing pathways. Further work will be needed to determine which proteolytic pathways contribute to presentation of Mtb T7SS substrates on MHC-I.
In addition to T7SS substrates, we also identified peptides derived from a Sec pathway substrate (TB8.4), and from uncharacterized hypothetical proteins (Rv1211, Rv3196A). Rv1211 and Rv3196A have both previously been detected by MS in culture filtrates of Mtb (Bell et al., 2012), as has the Mycobacterium marinum ortholog of Rv3196A (MMAR_1367; Cronin et al., 2022), suggesting that either or both of these proteins could be secreted despite lacking readily identifiable secretion signals. TB8.4, Rv1211, and Rv3196A are all low-molecular-weight proteins, which we speculate could make it easier for them to translocate through pores in a permeabilized phagosomal membrane. Further investigation of the localization of these proteins may help us better understand how and to what extent small secreted Mtb proteins other than known T7SS substrates can contribute to the MHC-I repertoire.
Some of the Mtb MHC-I peptides we identified derive from proteins known or suspected to be associated with the mycobacterial outer membrane (Abdallah et al., 2006; Sampson et al., 2001). These include PPE51 (Wang et al., 2020), PPE20 (Boradia et al., 2022), PPE60 (Su et al., 2018), EspC (Champion et al., 2009; Lou et al., 2017), and PE13 [the co-transcribed binding partner (Chen et al., 2017) of the putative outer membrane protein PPE18 (Nair et al., 2009)]. While some of these proteins can also be found in soluble form in culture filtrates (Tufariello et al., 2016), others may be stably associated with the mycobacterial outer membrane (Wang et al., 2020). The mechanism by which antigens associated with the outer membrane are processed and presented could differ from that of soluble secreted proteins.
Prior work shows that at least some of the MHC-I antigens we identified as potential vaccine targets are immunogenic in humans. Lewinsohn et al., 2017 showed that in humans with prior exposure to Mtb, EsxA, EsxB, PPE51, and EsxJKPW are sources of immunodominant CD8+ T cell antigens, while other antigens identified in our study elicited intermediate responses (PE13, PE35, PPE60, PPE19), and one elicited no detectable response (PPE20). In a separate study, CD8+ T cells (as well as CD4+ T cells) recognized multiple epitopes derived from EspC (Millington et al., 2011). Individual peptides we identified by MS have also been previously shown to be recognized by human T cells, including EsxJ24-34 (Grotzke et al., 2010; Lewinsohn et al., 2013) and EsxA28-36 (Tully et al., 2005), providing a proof of concept that particular epitopes identified by MS can be immunogenic. Antigens like PPE20 that did not elicit measurable CD8+ T cell responses in the context of natural infection should not necessarily be ruled out as vaccine targets, as a lack of CD8+ T cell recognition in the setting of natural infection does not necessarily imply that these antigens could not be immunogenic. Bioinformatic studies have also shown that predicted class I HLA-binding motifs are statistically underrepresented in several Esx-family protein sequences, suggesting that these proteins may be under selective pressure to escape recognition by CD8+ T cells (Maman et al., 2011). This finding provides further support for the idea that T cell recognition of T7SS substrates presented on MHC-I is functionally relevant to protective immunity against Mtb infection.
We did not detect any peptides derived from several antigens previously shown to stimulate CD8+ T cell responses in Mtb infection, including responses restricted to HLA alleles represented in our DDA MS analyses [for example, EsxH and FbpB (Axelsson-Robertson et al., 2015)]. This could be due to any of several biological and/or technical reasons. Given that the Mtb-derived MHC-I peptides we detected were enriched for T7SS substrates but not for substrates of the Sec or Tat secretion pathways, it is possible that the subcellular localization of antigens secreted via these pathways is not optimal for efficient presentation on MHC-I in macrophages. In this case, other types of APCs that differ in their antigen processing and presentation capabilities could still present peptides from these antigens to prime the previously observed CD8+ T cell responses. The same could also be true of certain T7SS substrate antigens (such as EsxH) if T7SS substrates vary in their subcellular localization or if presentation of certain epitopes requires antigen processing pathways not active in macrophages. In future studies, isolating MHC peptides from multiple myeloid cell types may help determine whether heterogeneity in antigen presentation among cell types contributes to apparent discrepancies between the Mtb-specific CD8+ T cell repertoire and the macrophage pMHC repertoire. Some peptides may also have been missed because they were lost to adsorption during sample handling, because they were below the limit of detection due to low abundance or ionization efficiency, or because they co-eluted with other, more abundant peptides and were therefore not prioritized for acquisition in DDA analyses. In future work, pMHC internal standards added prior to immunoprecipitation may enable accurate estimates of the limit of MS detection for specific peptides, to determine whether technical factors led to a lack of detection. Our results do not rule out presentation of additional categories of antigens besides those we detected.
Our results identify several Mtb proteins that are accessible for presentation on MHC-I in Mtb-infected human macrophages, suggesting that these could serve as targets for subunit vaccines designed to elicit CD8+ T cell-mediated protection against TB. By showing that T7SS substrates are overrepresented in the MHC-I repertoire of macrophages and revealing mechanistic determinants of Mtb antigen processing, our results have the potential to guide future screens to identify additional vaccine targets. Our findings advance the field’s understanding of antigen presentation in TB and suggest novel potential targets for TB vaccine development.
MethodsHuman cell isolation, differentiation, and culture
Deidentified buffy coats were obtained from Massachusetts General Hospital. Samples are acquired and provided to research groups with no identifying information. HLA-A*02:01+, HLA-B*57:01+leukapheresis samples (leukopaks) were obtained from StemCell. PBMCs were isolated by density-based centrifugation using Ficoll (GE Healthcare). CD14 +monocytes were isolated from PBMCs using a CD14 positive-selection kit (Stemcell). Isolated monocytes were differentiated in R10 media [RPMI 1640 without phenol red (Gibco) supplemented with 10% heat-inactivated FBS (Gibco), 1% HEPES (Corning), 1% L-glutamine (Sigma)] supplemented with 25 ng/mL M-CSF (Biolegend, 572902). Monocytes were cultured on appropriate ultra-low-attachment plates or flasks (Corning) for 6 days.
For ELISA assays, Cathepsin B activity assays, and growth curves (see below), after 6 days macrophages were detached using a detachment buffer of calcium-free PBS and 2 mM ethylenediaminetetraacetic acid (EDTA), pelleted, and recounted. Macrophages were plated in tissue culture treated 96-well plates at a density of 50,000 cells per well in R10 media and allowed to re-adhere overnight prior to infection. For microscopy (see below) cells were similarly detached and were replated on 12-well chamber slides (Ibidi) at a density of 100,000 cells per well in R10 media and allowed to re-adhere overnight prior to infection. For all other experiments, macrophage differentiation media was replaced with fresh R10 overnight prior to infection, without re-plating the macrophages.
HLA genotyping
Genomic DNA was extracted from 5x106 PBMCs using a Qiagen DNeasy kit. HLA typing was performed using a targeted next generation sequencing (NGS) method. Briefly, locus-specific primers were used to amplify a total of 26 polymorphic exons of HLA-A & B (exons 1–4), C (exons 1–5), E (exon 3), DPA1 (exon 2), DPB1 (exons 2–4), DQA1 (exon 1–3), DQB1 (exons 2 & 3), DRB1 (exons 2 & 3), and DRB3/4/5 (exon 2) genes with Fluidigm Access Array system (Fluidigm Corporation, South San Francisco, CA 94080 USA). The 26 Fluidigm PCR amplicons were harvested from Fluidigm Access Allay IFC and pooled. Quality and quantity were checked using a Caliper LabChip GX Touch HT Nucleic Acid Analyzer (PerkinElmer, Waltham, MA 02452 USA). The PCR product library was quantitated and subjected to sequencing on an Illumina MiSeq sequencer (Illumina, San Diego, CA 92122 USA). HLA alleles and genotypes were called using the Omixon HLA Explore (version 2.0.0) software (Omixon Biocomputing Ltd., Budapest, Hungary).
<italic>Mtb</italic> culture
Mycobacterium tuberculosis (Mtb) H37Rv was grown in Difco Middlebrook 7H9 media supplemented with 10% OADC, 0.2% glycerol, and 0.05% Tween-80 to mid-log phase. Strains expressing GFP were grown in media supplemented with 50 μg/mL hygromycin B (Sigma-Aldrich), and strains expressing luxABCDE were grown in media supplemented with 20 μg/mL Zeocin (Thermo).
<italic>Mtb</italic> infection of macrophages
The Mtb culture was pelleted by centrifugation, washed once with PBS, resuspended in R10 media and filtered through a 5 μm syringe filter to obtain a single-cell suspension. Macrophages were infected at the indicated multiplicity of infection (MOI) for 4 hr and then washed with PBS to remove extracellular Mtb. Infected macrophages were cultured in R10 media for the remainder of the experiment.
Drug treatment of macrophages
Where indicated, macrophages were pre-treated with R10 media containing 20 μM E64d (Cayman), 0.5 μM MG-132 (Cayman), or 10 nM bafilomycin (InvivoGen), or DMSO alone (or other concentration of drug where indicated). The culture media was supplemented with an equal concentration of drug during infection with Mtb, and after washing off extracellular Mtb. Where indicated, the culture media was supplemented with 10 ng/mL of IFN-β after infection with Mtb.
hipMHC internal standard preparation
UV-mediated peptide exchange and quantification of hipMHC complexes by ELISA were performed as previously described (Stopfer et al., 2020). Amidated peptides with sequences AL[+7]ADGVQKV-NH2, ALNEQIARL[+7]-NH2, and SLPEEIGHL[+7]-NH2 were used to make hipMHC standards.
MHC-I immunoprecipitation (IP)
A total of 50 million macrophages per condition (data-dependent analysis) or 10 million macrophages per condition (quantitative SureQuant analysis) were cultured as described above in ultra-low-attachment T75 flasks (Corning). macrophages were infected at MOI 2.5 as described above, or mock-infected with media containing no Mtb. Where indicated for specific DDA MS experiments (donor B), the culture media was supplemented with 10 ng/mL of IFN-γ for 24 hr prior to infection with Mtb. Where indicated for specific DDA MS experiments (donor C), the culture media was supplemented with 0.5 µg/mL of cycloheximide for the final 6 hr of culture prior to MHC-I isolation. Seventy-two hr post-infection, cells were detached using PBS supplemented with 2 mM EDTA, washed with PBS, and lysed in 1 mL (DDA analysis) or 0.5 mL (SureQuant analysis) of MHC lysis buffer [20 mM Tris, 150 mM sodium chloride, pH 8.0, supplemented with 1% CHAPS, 1 x HALT protease and phosphatase inhibitor cocktail (Pierce), and 0.2 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich)]. Lysate was sonicated using a Q500 ultrasonic bath sonicator (Qsonica) in five 30 s pulses at an amplitude of 60%, cleared by centrifugation at 16,000 x g, and sterile filtered twice using 0.2 μm filter cartridges (Pall NanoSep). For quantitative SureQuant analyses, the protein concentration of the lysates was normalized by BCA assay (Pierce), and 100 fmol of each hipMHC standard was added to each sample. Lysates were then added to protein A sepharose beads pre-conjugated to pan-MHC-I antibody (clone W6/32), prepared as previously described (Stopfer et al., 2020), and incubated rotating at 4 °C overnight (12–14 hours). Beads were then washed and peptide-MHC complexes eluted as previously described (Stopfer et al., 2020).
Purification of MHC-I-associated peptidesProtocol 1
MHC-I-associated peptides were purified using 10 kDa molecular weight cutoff filters (Pall NanoSep) as previously described (Stopfer et al., 2020), snap-frozen in liquid nitrogen, and lyophilized.
Protocol 2
C18 SpinTips (Pierce) were washed with 0.1% trifluoroacetic acid, activated with 90% acetonitrile supplemented with 0.1% formic acid, and washed with 0.1% formic acid. Eluate from MHC-I IPs was applied to the column by centrifugation. The column was washed with 0.1% formic acid, and peptides were eluted by applying elution solvent (30% acetonitrile supplemented with 0.1% formic acid) by centrifugation twice. Eluates were snap-frozen in liquid nitrogen and lyophilized. Lyophilized peptides were resuspended in solvent A2 (10 mM triethyl ammonium bicarbonate [TEAB], pH 8.0) and loaded onto a fractionation column (a 200 μm inner diameter fused silica capillary packed in-house with 10 cm of 10 μM C18 beads). Peptides were fractionated using an Agilent 1100 series liquid chromatograph using buffers A2 (10 mM TEAB, pH 8.0) and B2 (99% acetonitrile, 10 mM TEAB, pH 8.0). The fractionation column was washed with solvent A2, and peptides were separated using a gradient of 1–5% solvent B2 over 5 min, 5–40% over 60 min, 40–70% over 10 min, hold for 9 min, and 70%–1% over 1 min. Ninety-second fractions were collected, concatenated into 12 tubes, over 90 min in total. Fractions were flash-frozen in liquid nitrogen and lyophilized.
DDA MS analyses
MHC-I peptide samples were resuspended in 0.1% formic acid. 25% of the sample was refrozen and reserved for later SureQuant validation analyses, while 75% of the sample was used for DDA analysis. For all MS analyses, samples were analyzed using an Orbitrap Exploris 480 mass spectrometer (Thermo Fisher Scientific) coupled with an UltiMate 3000 RSLC Nano LC system (Dionex), Nanospray Flex ion source (Thermo Fisher Scientific), and column oven heater (Sonation). The MHC peptide sample was loaded onto a fused silica capillary chromatography column with an integrated electrospray tip (~1 μm orifice) prepared and packed in-house with 10 cm of 1.9 μm C18 beads (ReproSil-Pur).
Standard mass spectrometry parameters were as follows: spray voltage, 2.0 kV; no sheath or auxiliary gas flow; ion transfer tube temperature, 275 °C. The Orbitrap Exploris 480 mass spectrometer was operated in data dependent acquisition (DDA) mode. Peptides were eluted using a gradient of 6–25% buffer B (70% Acetonitrile, 0.1% formic acid) over 75 min, 25–45% over 5 min, 45–100% over 5 min, hold for 1 min, and 100% to 3% over 2 min. Full scan mass spectra (350–1200 m/z, 60,000 resolution) were detected in the orbitrap analyzer after accumulation of 3x106 ions (normalized AGC target of 300%) or 25ms. For every full scan, MS/MS scans were collected during a 3 s cycle time. Ions were isolated (0.4 m/z isolation width) using the standard AGC target and automatic determination of maximum injection time, fragmented by HCD with 30% CE, and scanned at a resolution of 45,000. Charge states <2 and>4 were excluded, and precursors were excluded from selection for 30 s if fragmented n=2 times within a 20-s window.
DDA data search and manual inspection
All mass spectra were analyzed with Proteome Discoverer (PD, version 2.5) and searched using Mascot (version 2.4) against a custom database comprising the Uniprot human proteome (UP000005640) and the Uniprot Mycobacterium tuberculosis H37Rv proteome (UP000001584). No enzyme was used, and variable modifications included oxidized methionine for all analyses. Peptide-spectrum matches from all analyses were filtered with the following criteria: search engine rank = 1, isolation interference ≤30%, length between 8 and 16 amino acids, ions score ≥15, and percolator q-value <0.05. Identifications (IDs) of putative Mtb-derived peptides were rejected if any peptide-spectrum matches (PSMs) for the same peptide were found in the unfiltered DDA MS data for the corresponding mock-infected control. For each putative Mtb peptide identified, MS/MS spectra and extracted ion chromatograms (XIC) were manually inspected, and the ID was only accepted for further validation if it met the following criteria: (1) MS/MS spectra contained enough information to unambiguously assign a majority of the peptide sequence; (2) neutral losses were consistent with the chemical properties of the peptide; (3) manual de novo sequencing did not reveal an alternate peptide sequence that would explain a greater number of MS/MS spectrum peaks; (4) XIC showed a peak in MS intensity at the mass to charge ratio (m/z) of the peptide precursor ion at the retention time at which it was identified that did not appear in the corresponding mock-infected control. Peptides that met these criteria were further validated using SureQuant (see below).
DDA MS data were searched a second time against a database comprising only known T7SS substrates of Mtb H37Rv (all Esx-family proteins, all PE/PPE proteins, and EspA, EspB, EspC, EspE, EspF, EspI, EspJ, and EspK). Because high sequence similarity among many T7SS substrates artificially raises percolator q-values computed using this limited database, these searches were filtered only on ions score ≥20 rather than on ions score ≥15 and percolator q-value <0.05. The only validated Mtb peptide identified via these additional searches that had not previously been identified (AEHGMPGVP, derived from PPE51) was omitted from enrichment analyses (see below) to avoid introducing bias.
Gibbs clustering
Host peptides and putative Mtb peptides that passed the filters described above were clustered using GibbsCluster 2.0 (Andreatta et al., 2017), hosted at (https://services.healthtech.dtu.dk/service.php?GibbsCluster-2.0). Default parameters for MHC-I peptide clustering were used, with the modification that a maximum of 6 clusters was allowed. The number of clusters that gave the highest KL divergence score was considered optimal. Clusters were assigned to HLA alleles by comparing cluster motifs to the known sequence binding motifs obtained from the NetMHCpan 4.1 motif viewer (Reynisson et al., 2020) (https://services.healthtech.dtu.dk/service.php?NetMHCpan-4.1) for HLA alleles expressed by that donor.
HLA allele assignment
For each donor, the binding affinity of Mtb peptides identified in DDA MS data for each HLA allele expressed by that donor (as determined by HLA typing – see above) was predicted using NetMHCpan 4.1 (Reynisson et al., 2020). Peptides were assigned to the allele for which they had the highest predicted binding score.
Enrichment analyses
To determine whether Mtb-derived MHC-I peptides or their source proteins were enriched for proteins with specific secretion signals, we classified each protein in the reference Mtb H37Rv proteome (UP000001584) using SignalP 6.0 (Teufel et al., 2022), and added an additional class of known T7SS substrates (as defined above; see DDA data search). Under a ‘neutral model’ in which all possible Mtb peptides are equally likely to be presented, the probability of drawing a peptide from a given class of proteins can be approximated as the sum of the lengths of the amino acid sequences of proteins in that class, divided by the total number of amino acid residues in the Mtb proteome. Using this approximation, we used a binomial test to assess whether the number of Mtb-derived peptides from each class of proteins detected in the MHC-I was greater or less than would be predicted under the neutral model. We used a hypergeometric test to assess whether the number of source proteins from each class was greater or less than expected, relative to a neutral model in which each protein in the Mtb proteome is equally likely to contribute to the MHC-I repertoire.
SIL peptide synthesis
SIL peptides were synthesized at the MIT Biopolymers and Proteomics Lab using standard Fmoc chemistry using an Intavis model MultiPep peptide synthesizer with HATU activation and 5 μmol chemistry cycles. Starting resin used was Fmoc-Amide Resin (Applied Biosystems). Cleavage from resin and simultaneous amino acid side chain deprotection was accomplished using: trifluoroacetic acid (81.5% v/v); phenol (5% v/v); water (5% v/v); thioanisole (5% v/v); 1,2-ethanedithiol (2.5% v/v); 1% triisopropylsilane for 4 hr. Standard Fmoc amino acids were procured from NovaBiochem and SIL Fmoc-Leu (13C6, 15N), Fmoc-Arg (13C6), Fmoc-Glu (13C515N) were obtained from Cambridge Isotope Laboratories. Peptides were quality controlled by MSy and reverse phase chromatography using a Bruker MicroFlex MALDI-TOF and Agilent model 1100 HPLC system with a Vydac C18 column (300 Å, 5 μm, 2.1×150 mm2) at 300 μL/min monitoring at 210 and 280 nm with a trifluoroacetic acid/H2O/MeCN mobile phase survey gradient.
Synthetic standard survey MS analyses
DDA MS analysis of the SIL peptide mixture was performed as described above (see DDA MS analyses) with the following modifications: Peptides were eluted using a gradient of 6–35% buffer B over 30 min, 35–45% over 2 min, 45–100% over 3 min, and 100% to 2% over 1 min. No dynamic exclusion was used.
A second set of survey analyses was performed on the mixture of SIL peptides with background matrix using the full SureQuant acquisition method (see below). SIL peptides were spiked into a mixture of MHC-I peptides purified as described above from THP-1 cells differentiated into macrophages via 24 hr of treatment with 150 nM phorbol myristate acetate (PMA), which provided a representative background matrix. Because SIL amino acids are not 100% pure, SIL peptide concentrations were adjusted and survey analyses were repeated until the SIL peptide could be reliably detected while minimizing background signal detected at the mass of the biological peptide.
SureQuant MS analysesValidation analyses
Standard MS parameters and MS1 scan parameters were as described above (see DDA MS analyses). The custom SureQuant acquisition template available in Thermo Orbitrap Exploris Series 2.0 was used to build four methods for validation analyses. One method targeted peptides detected in DDA analyses of the MHC-I repertoire of macrophages from donors A, B, and C. The other three methods targeted peptides detected in DDA analyses of the MHC-I repertoire of macrophages from donors D, E, and F, respectively. For each method, after the optimal charge state and most intense product ions were determined via a survey analysis of the synthetic SIL peptide standards (see above), one method branch was created for each m/z offset between the SIL peptide and biological peptide as previously described (Stopfer et al., 2020). A threshold of n=3 out the top 6 product ions was used for pseudo-spectral matching, with a mass accuracy tolerance of 10 ppm.
Quantitative analyses
Quantitative SureQuant analyses were performed similarly, with an additional method branch added to target hipMHC peptides using an inclusion list. As none of the targets of these analyses has an m/z<380, an MS1 scan range of m/z 380–1500 was used to exclude some common background ions. Targeted MS data were analyzed using Skyline Daily Build 22.1.9.208. For each target peptide, the intensities of the three most intense product ions were integrated over the time during which the peptide was scanned. These intensities were normalized by the integrated intensities of the corresponding product ions from the corresponding SIL standard over the same time interval, and these ratios were averaged. Finally, these averaged ratios were normalized by the average ratio of the integrated intensities of the hipMHC standard peptides and normalized to the DMSO-treated, Mtb-infected condition to obtain the final relative abundance of each target. 100 fmol of SIL EsxA28-36 and 1 pmol of SIL EsxJKPW24-34 were spiked into each sample per analysis, as well as (where indicated) 250 fmol of SIL standard for each of the target self peptides.
Immunofluorescence microscopy
100,000 macrophages per well plated on chamber slides (Ibidi) were infected with GFP-expressing Mtb at MOI 1 or mock-infected with media containing no Mtb. At the indicated time point post-infection, macrophages were washed with PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 1 hr. After the full time course was collected, all slides were blocked with 5% normal goat serum in PBS supplemented with 0.3% v/v Triton X-100 for 1 hr at room temperature and stained overnight at 4 °C with primary antibody (LAMP1 – Cell Signaling Technologies [CST] D2D11; P62 – CST D10E10; MHC-I – CST D8P1H; Galectin-3 – Thermo A3A12) diluted in antibody dilution buffer (PBS with 1% w/v bovine serum albumin and 0.3% v/v triton X-100). Wells were washed three times with PBS for 5 min each and stained with Alexa fluor 647 (AF647)-conjugated goat anti-rabbit or anti-mouse secondary antibody (Thermo) diluted to a final concentration of 1 μg/mL in antibody dilution buffer at room temperature for 2 hr. Wells were washed three times with PBS for 5 min each and stained with DAPI at a final concentration of 300 nM in PBS for 15 min at room temperature. Wells were washed three times with PBS for 5 min each, well dividers were removed, and slide covers were mounted on slides using Prolong Diamond anti-fade mounting media (Thermo). Slides were imaged using a TissueFAXS Confocal slide scanner system (TissueGnostics). 100 fields of view were acquired per condition using a ×40 objective lens.
Segmentation of <italic>Mtb</italic>-containing phagosomes
Image segmentation was performed using opencv-python 4.5.4.60. A two-dimensional Gaussian blur with a standard deviation of five pixels was applied to de-noise GFP fluorescence images. A binary mask was generated from the blurred GFP image using a fluorescence intensity threshold that was empirically selected for each biological replicate. GFP +phagosomes were further segmented using the watershed algorithm.
Colocalization analysis
A correlation image was generated by computing the Pearson correlation coefficient between the GFP fluorescent intensity and AF647 fluorescent intensity in a 41x41 pixel sliding window with a step size of 1. This correlation value was averaged over each Mtb-containing phagosome, and phagosomes with a mean value of greater than or equal to 0.6 were considered co-localized. For statistical analyses of log-transformed rates of co-localization, zeros were replaced with the limit of detection for a given sample (100% x [1 /N] where N is the number of Mtb-containing phagosomes detected).
<italic>Mtb</italic> growth curves
A total of 50,000 macrophages per well were infected in technical triplicate in opaque white 96-well plates with luxABCDE-expressing Mtb at MOI 2.5 (or mock-infected with media not containing Mtb). Where indicated, macrophages were treated with drug as described above, or media was supplemented with 10 ng/mL IFN-β (BioLegend) or 25 μg/mL rifampicin (RIF) after infection. Luminescence was measured at the indicated time points using a Spark 10 M plate reader (Tecan).
Phagocytosis assay
1x106 macrophages were differentiated as described above on six-well ultra low-attachment plates and infected with GFP-expressing Mtb at an MOI of 2.5 (or mock-infected with media containing no Mtb). After the 4 hr infection, macrophages were detached using PBS supplemented with 2 mM EDTA, washed with PBS, stained with Live/Dead Fixable Near-IR dye (Thermo) for 10 min, washed with FACS buffer (PBS supplemented with 2% FBS and 2 mM EDTA) and PBS, fixed with PBS containing 4% PFA for one hour, and washed and resuspended in FACS buffer for analysis on an LSRFortessa flow cytometer (BD).
MHC-I and MHC-II flow cytometry
A total of 1x106 macrophages were differentiated as described above on six-well ultra low-attachment plates and infected with GFP-expressing Mtb at an MOI of 2.5 (or mock-infected with media containing no Mtb). Seventy-two hr post-infection, macrophages were detached using PBS supplemented with 2 mM EDTA, blocked with Human TruStain FcX Fc receptor blocking solution (BioLegend) for 10 min, stained with phycoerythrin (PE)-conjugated anti-HLA-A,B,C antibody (BioLegend, clone W6/32) or PE-conjugated anti-HLA-DQ antibody (BioLegend, clone HLA-DQ1) and PerCP-Cy5.5-conjugated anti-HLA-DR antibody (BioLegend, clone L243) for 20 min, stained with Live/Dead Fixable Near-IR dye (Thermo) for 10 min, washed with FACS buffer and PBS, fixed with PBS containing 4% PFA for 1 hr, and washed and resuspended in FACS buffer for analysis on an LSR Fortessa flow cytometer (BD).
ELISA
A total of 50,000 macrophages per well were infected in technical triplicate in a 96-well plate format with Mtb at MOI 2.5 (or mock-infected with media not containing Mtb). Seventy-two hr post-infection, culture media was collected and sterile filtered twice by centrifugation using 96-well 0.2 μm filter plates (Corning). The concentration of CXCL10 in the media was determined using a Human CXCL10 ELISA MAX kit (BioLegend 439904).
LDH release assay
A total of 50,000 macrophages per well were infected in technical triplicate in a 96-well plate format with Mtb at MOI 2.5 (or mock-infected with media not containing Mtb) and treated with the indicated concentrations of drug or vehicle control. Twenty-four hr post-infection, culture media was collected and sterile filtered twice by centrifugation using 96-well 0.2 μm filter plates (Corning). Percent cytotoxicity was determined using a CyQuant LDH Cytotoxicity Assay kit (Thermo C20300).
Western blots
On six-well ultra low-attachment plates, 1x106 macrophages were differentiated as described above . Where indicated, macrophages were infected with Mtb at an MOI of 2.5. Macrophages were treated for 24 hr with the indicated concentration of MG-132 or DMSO control, and were then detached using PBS supplemented with 2 mM EDTA, washed with PBS, pelleted, and lysed in 100 μL RIPA buffer. Lysates were cleared by centrifugation at 16,000 x g for 5 min. For cells infected with Mtb, lysates were filtered twice using 96-well 0.2 μm filter plates (Corning). NuPAGE LDS Sample Buffer (Thermo) and NuPAGE Sample Reducing Agent (Thermo) were added to a final concentration of 1 x, and 20 μL of lysate per well was separated by SDS-PAGE. Protein was transferred to a PVDF membrane using an iBlot2 dry transfer system (Thermo). Membranes were blocked for 1 hr at room temperature with blocking buffer (Licor) and incubated overnight at 4 °C with anti-K48-linked poly-ubiquitin antibody (Cell Signaling Technologies) and anti-β-actin antibody (Santa Cruz Biotechnologies), each diluted 1:1000 in antibody diluent (Licor). Blots were washed three times for 5 min each with tris-buffered saline with 0.1% tween-20 (TBS-T) and incubated for 1 hr at room temperature with IRDye 800CW goat anti-rabbit secondary antibody (Licor) and IRDye 680CW goat anti-mouse secondary antibody (Licor), each diluted 1:10,000 in antibody diluent (Licor). Blots were washed three times for five minutes each with TBS-T and imaged using an Odyssey DLx imaging system (Licor).
Cathepsin B activity assays
Cathepsin B activity was measured using an assay protocol adapted from prior literature (Creasy et al., 2007; Hulkower et al., 2000). 50,000 macrophages per well were infected in technical triplicate in a 96-well plate format with Mtb at MOI 2.5 (or mock-infected with media not containing Mtb) and treated with the indicated concentrations of E64d or vehicle control. Twenty-four hr post-infection, macrophages were washed with PBS and lysed by adding 100 μL assay buffer (87.7 mM KH2PO4,12.3 mM NaHPO4, 4 mM EDTA, pH 5.5) supplemented with 2.6 mM dithiothreitol and 0.1% v/v Triton X-100, mixing thoroughly, and incubating at 37 °C for 15 min. Forty μL of lysate was transferred to a separate 96-well plate, and the fluorogenic cathepsin B substrate Z-RR-AMC (Sigma-Aldrich) diluted in assay buffer was added to a final concentration of 2 mM. Plates were immediately transferred to a Spectramax iD3 plate reader (Molecular Devices) pre-warmed to 37 °C. Fluorescence at an absorbance wavelength of 370 nm and emission wavelength of 460 nm was measured in kinetic read mode at intervals of 2 min for a total duration of 20 min. The linear (enzyme-limited) regime of the fluorescence curve was determined to last approximately 10 min, so cathepsin B activity was quantified by using linear regression to determine the initial rate of fluorescence increase over the first 10 min of the assay.
Lysotracker microscopy
A total of 100,000 macrophages per well plated on chamber slides (Ibidi) were infected with GFP-expressing Mtb at MOI 2.5 (or mock-infected with media containing no Mtb) and treated with bafilomycin or vehicle control as described above. Twenty-four hr post-infection, macrophages were washed with Hank’s Balanced Salt Solution (HBSS), then incubated for 5 min at 37 °C in pre-warmed HBSS containing 1 μM Lysotracker Red (Thermo). Cells were washed twice with HBSS and fixed with PBS containing 4% PFA for 1 hr, then stained with DAPI and mounted as described above (see immunofluorescence microscopy). Slides were imaged using a TissueFAXS Confocal slide scanner system (TissueGnostics). Using a ×40 objective lens, 100 fields of view were acquired per condition.
Automated counting of nuclei
Image segmentation was performed using opencv-python 4.5.4.60. A two-dimensional Gaussian blur with a standard deviation of five pixels was applied to de-noise DAPI fluorescence images. A binary mask was generated from the smoothed DAPI image using a fluorescence intensity threshold that was determined automatically using Otsu’s thresholding method, as implemented in opencv-python. To disambiguate adjacent or overlapping nuclei, nuclei were further segmented using the watershed algorithm.
Calculation of Lysotracker+ area per cell
A two-dimensional Gaussian blur with a standard deviation of five pixels was applied to de-noise Lysotracker Red fluorescence images. A binary mask was generated from the Lysotracker Red image using a fixed intensity threshold for all samples. The total Lysotracker +area was computed from the binary mask and divided by the number of nuclei counted in the image (see above).
Curve fitting and statistical analyses
Unless otherwise indicated, all nonlinear curve fitting and all statistical tests were performed in GraphPad Prism 9.
Additional informationCompeting interests
No competing interests declared
Author contributions
Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing
Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing
Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing
Additional filesData availability
The mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2022) partner repository with the dataset identifiers PXD037837 (DDA data) and PXD037843 (SureQuant data). Microscopy data analysis scripts are available on GitHub at https://github.com/oleddy/local_correlation_analysis (copy archived at Leddy, 2023).
The following datasets were generated:
BrysonBD2023DDA dataPRIDEPXD037837
BrysonBD2023SureQuant dataPRIDEPXD037843
Acknowledgements
The authors thank all the staff members of the Ragon Institute, the Koch Institute, and MIT for the essential work they do to make our research possible. The authors thank Lauren Stopfer, Akeem Ngomu Akilimali, Sean Kim, Elizabeth Choe, Charul Jani, Yong Xie (Ragon Institute BSL3 Facility), Thomas Diefenbach (Ragon Institute Microscopy Core Facility), Tigist Tamir, Cameron Flower, Angela Ahn, Kiera Clayton, and Aaron Shulkin for helpful conversations, training, and technical guidance. Iris Abrahantes Morales isolated monocytes from buffy coats. The authors thank Yuko Yuki and Mary Carrington (National Cancer Institute) for HLA genotyping of primary human cells. Kiera Clayton generously shared HLA-A*02:01+, HLA-B*57:01+PBMCs from a leukapheresis sample for one biological replicate. The eccCa1:Tn Mtb strains used in this study were generously provided by Charul Jani and Amy Barczak. Diane Ballestas and Isadora Deese provided administrative support. Alla Leshinsky, Heather Amoroso, and Richard Cook (Koch Institute Biopolymers Core Facility) synthesized and purified SIL peptide standards. We modified code written by Cameron Flower to plot MS/MS spectra. The authors thank the staff of the Ragon Institute Flow Cytometry Core Facility. This work was supported by funding from NIH grants R35GM142900-01 and R01A1022553, NIEHS grant P42 ES027707, and the Center for Precision Cancer Medicine. This work was performed in part in the Ragon Institute BSL3 core, which is supported by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354).
ReferencesAbdallahAMVerboomTHannesFSafiMStrongMEisenbergDMustersRJPVandenbroucke-GraulsCMJEAppelmelkBJLuirinkJBitterW2006A specific secretion system mediates PPE41 transport in pathogenic mycobacteriaMolecular Microbiology6266767910.1111/j.1365-2958.2006.05409.x17076665AbdallahAMGey van PittiusNCChampionPADCoxJLuirinkJVandenbroucke-GraulsCMJEAppelmelkBJBitterW2007Type VII secretion -- mycobacteria show the wayNature Reviews. Microbiology588389110.1038/nrmicro177317922044AndreattaMAlvarezBNielsenM2017GibbsCluster: unsupervised clustering and alignment of peptide sequencesNucleic Acids Research45W458W46310.1093/nar/gkx24828407089ArmstrongJAHartPD1975Phagosome-Lysosome interactions in cultured macrophages infected with virulent tubercle bacilli: reversal of the usual nonfusion pattern and observations on bacterial survivalThe Journal of Experimental Medicine14211610.1084/jem.142.1.1807671AugenstreichJArbuesASimeoneRHaanappelEWegenerASayesFLe ChevalierFChalutCMalagaWGuilhotCBroschRAstarie-DequekerC2017Esx-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosisCellular Microbiology19e1272610.1111/cmi.1272628095608Axelsson-RobertsonRJuJHKimHYZumlaAMaeurerM2015Mycobacterium tuberculosis-specific and MHC class I-restricted CD8+ T-cells exhibit a stem cell precursor-like phenotype in patients with active pulmonary tuberculosisInternational Journal of Infectious Diseases32132210.1016/j.ijid.2014.12.017BeckwithKSBeckwithMSUllmannSSætraRSKimHMarstadAÅsbergSEStrandTAHaugMNiederweisMStenmarkHAFloTH2020Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infectionNature Communications11227010.1038/s41467-020-16143-632385301BellCSmithGTSweredoskiMJHessS2012Characterization of the Mycobacterium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis researchJournal of Proteome Research1111913010.1021/pr200793922053987BettencourtPMüllerJNicastriACantillonDMadhavanMCharlesPDFotsoCBWittenbergRBullNPinpathomratNWaddellSJStylianouEHillAVSTernetteNMcShaneH2020Identification of antigens presented by MHC for vaccines against tuberculosisNPJ Vaccines5210.1038/s41541-019-0148-y31908851BoradiaVFrandoAGrundnerC2022Calcium Transport by the Mycobacterium Tuberculosis PE15/PPE20 ProteinsbioRxiv10.1101/2022.05.30.494056BursterTMacmillanHHouTBoehmBOMellinsED2010Cathepsin G: roles in antigen presentation and beyondMolecular Immunology4765866510.1016/j.molimm.2009.10.00319910052ChampionPADStanleySAChampionMMBrownEJCoxJS2006C-Terminal signal sequence promotes virulence factor secretion in Mycobacterium tuberculosisScience3131632163610.1126/science.113116716973880ChampionPADChampionMMManzanilloPCoxJS2009Esx-1 secreted virulence factors are recognized by multiple cytosolic AAA ATPases in pathogenic mycobacteriaMolecular Microbiology7395096210.1111/j.1365-2958.2009.06821.x19682254ChauhanSKumarSJainAPonpuakMMuddMHKimuraTChoiSWPetersRMandellMBruunJAJohansenTDereticV2016TRIMs and galectins globally cooperate and TRIM16 and galectin-3 co-direct autophagy in endomembrane damage homeostasisDevelopmental Cell39132710.1016/j.devcel.2016.08.00327693506ChenCYHuangDWangRCShenLZengGYaoSShenYHallidayLFortmanJMcAllisterMEstepJHuntRVasconcelosDDuGPorcelliSALarsenMHJacobsWRHaynesBFLetvinNLChenZW2009A critical role for CD8 T cells in a nonhuman primate model of tuberculosisPLOS Pathogens5e100039210.1371/journal.ppat.100039219381260ChenXChengH-FZhouJChanC-YLauK-FTsuiSK-WAuSW-N2017Structural basis of the PE-PPE protein interaction in Mycobacterium tuberculosisThe Journal of Biological Chemistry292168801689010.1074/jbc.M117.80264528842489CreasyBMHartmannCBWhiteFKHMcCoyKL2007New assay using fluorogenic substrates and immunofluorescence staining to measure cysteine cathepsin activity in live cell subpopulationsCytometry. Part A7111412310.1002/cyto.a.2036517200959CroninRMFerrellMJCahirCWChampionMMChampionPA2022Proteo-genetic analysis reveals clear hierarchy of ESX-1 secretion in Mycobacterium marinumPNAS119e212310011910.1073/pnas.212310011935671426DalekeMHvan der WoudeADParretAHAUmmelsRde GrootAMWatsonDPiersmaSRJiménezCRLuirinkJBitterWHoubenENG2012Specific chaperones for the type VII protein secretion pathwayThe Journal of Biological Chemistry287319393194710.1074/jbc.M112.39759622843727EkiertDCCoxJS2014Structure of a PE–PPE–espg complex from Mycobacterium tuberculosis reveals molecular specificity of Esx protein secretionPNAS111147581476310.1073/pnas.1409345111FinePEM1995Variation in protection by BCG: implications of and for heterologous immunityThe Lancet3461339134510.1016/S0140-6736(95)92348-9FlyerDCRamakrishnaVMillerCMyersHMcDanielMRootKFlournoyCEngelhardVHCanadayDHMartoJARossMMHuntDFShabanowitzJWhiteFM2002Identification by mass spectrometry of CD8 (+) -T-cell Mycobacterium tuberculosis epitopes within the rv0341 gene productInfection and Immunity702926293210.1128/IAI.70.6.2926-2932.200212010981FlynnJLGoldsteinMMTrieboldKJKollerBBloomBR1992Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infectionPNAS89120131201710.1073/pnas.89.24.120131465432FlynnJLChanJLinPL2011Macrophages and control of granulomatous inflammation in tuberculosisMucosal Immunology427127810.1038/mi.2011.1421430653FriguiWBottaiDMajlessiLMonotMJosselinEBrodinPGarnierTGicquelBMartinCLeclercCColeSTBroschR2008Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoPPLOS Pathogens4e3310.1371/journal.ppat.004003318282096FritscheJKowalewskiDJBackertLGwinnerFDornerSPriemerMTsouCCHoffgaardFRömerMSchusterHSchoorOWeinschenkT2021Pitfalls in HLA ligandomics-how to catch a Li (E) gandMolecular & Cellular Proteomics2010011010.1016/j.mcpro.2021.10011034129939GallienSKimSYDomonB2015Large-Scale targeted proteomics using internal standard triggered-parallel reaction monitoring (IS-PRM)Molecular & Cellular Proteomics141630164410.1074/mcp.O114.04396825755295GeierEPfeiferGWilmMLucchiari-HartzMBaumeisterWEichmannKNiedermannG1999A giant protease with potential to substitute for some functions of the proteasomeScience28397898110.1126/science.283.5404.9789974389GordonSVBroschRBillaultAGarnierTEiglmeierKColeST1999Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arraysMolecular Microbiology3264365510.1046/j.1365-2958.1999.01383.x10320585GrotzkeJEHarriffMJSilerACNoltDDelepineJLewinsohnDALewinsohnDM2009The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organellePLOS Pathogens5e100037410.1371/journal.ppat.100037419360129GrotzkeJESilerACLewinsohnDALewinsohnDM2010Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathwayJournal of Immunology1854336434310.4049/jimmunol.100080120802151GrotzkeJESenguptaDLuQCresswellP2017The ongoing SAGA of the mechanism (S) of MHC class I-restricted cross-presentationCurrent Opinion in Immunology46899610.1016/j.coi.2017.03.01528528219GuilSRodríguez-CastroMAguilarFVillasevilEMAntónLCDel ValM2006Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimentalJournal of Biological Chemistry281399253993410.1074/jbc.M608522200GuinnKMHickeyMJMathurSKZakelKLGrotzkeJELewinsohnDMSmithSShermanDR2004Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis: RD1 genes affect secretion and virulence of M. tuberculosisMolecular Microbiology5135937010.1046/j.1365-2958.2003.03844.xHulkowerKIButlerCCLinebaughBEKlausJLKepplerDGirandaVLSloaneBF2000Fluorescent microplate assay for cancer cell-associated cathepsin BEuropean Journal of Biochemistry2674165417010.1046/j.1432-1327.2000.01458.xIzquierdo LafuenteBUmmelsRKuijlCBitterWSpeerA2021Mycobacterium tuberculosis toxin cpnt is an ESX-5 substrate and requires three type VII secretion systems for intracellular secretionMBio12e02983-2010.1128/mBio.02983-2033653883KamathABWoodworthJXiongXTaylorCWengYBeharSM2004Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infectionThe Journal of Experimental Medicine2001479148910.1084/jem.2004169015557351KesslerJHKhanSSeifertULe GallSChowKMPaschenABres-VloemansSAde RuAvan MontfoortNFrankenKLMCBenckhuijsenWEBrooksJMvan HallTRayKMulderADoxiadisIINvan SwietenPFOverkleeftHSPratATomkinsonBNeefjesJKloetzelPMRodgersDWHershLBDrijfhoutJWvan VeelenPAOssendorpFMeliefCJM2011Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopesNature Immunology12455310.1038/ni.197421151101KloetzelPM2001Antigen processing by the proteasomeNature Reviews. Molecular Cell Biology217918710.1038/3505657211265247LázaroSGamarraDDel ValM2015Proteolytic enzymes involved in MHC class I antigen processing: a guerrilla army that partners with the proteasomeMolecular Immunology68727610.1016/j.molimm.2015.04.01426006050LeddyO2023Local correlation analysisswh:1:rev:da390142bcc385d4a3bd12275241291a626ad426Software Heritagehttps://archive.softwareheritage.org/swh:1:dir:39f77f0cbe8587a47955ba70bba162152bb07cb9;origin=https://github.com/oleddy/local_correlation_analysis;visit=swh:1:snp:bae11d47b63a1480bb3b697148891b588a693c0e;anchor=swh:1:rev:da390142bcc385d4a3bd12275241291a626ad426LeeJSKrauseRSchreiberJMollenkopfH-JKowallJSteinRJeonB-YKwakJ-YSongM-KPatronJPJorgSRohKChoS-NKaufmannSHE2008Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strainCell Host & Microbe39710310.1016/j.chom.2008.01.00218312844LewinsohnDMGrotzkeJEHeinzelASZhuLOvendalePJJohnsonMAldersonMR2006Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathwayJournal of Immunology17743744210.4049/jimmunol.177.1.43716785540LewinsohnDMSwarbrickGMCanslerMENullMDRajaramanVFriederMMShermanDRMcWeeneySLewinsohnDAShamsH2013Human Mycobacterium tuberculosis CD8 T cell antigens/epitopes identified by a proteomic peptide libraryPLOS ONE8e6701610.1371/journal.pone.0067016LewinsohnDASwarbrickGMParkBCanslerMENullMDTorenKGBasekeJZalwangoSMayanja-KizzaHMaloneLLNyendakMWuGGuinnKMcWeeneySMoriTChervenakKAShermanDRBoomWHLewinsohnDM2017Comprehensive definition of human immunodominant CD8 antigens in tuberculosisNPJ Vaccines2810.1038/s41541-017-0008-628775896LewisKNLiaoRGuinnKMHickeyMJSmithSBehrMAShermanDR2003Deletion of RD1 from Mycobacterium tuberculosis mimics Bacille Calmette-Guérin attenuationThe Journal of Infectious Diseases18711712310.1086/34586212508154LorenteEGarcíaRMirCBarrigaALemonnierFARamosMLópezD2012Role of metalloproteases in vaccinia virus epitope processing for transporter associated with antigen processing (TAP) -independent human leukocyte antigen (HLA) -B7 class I antigen presentationJournal of Biological Chemistry28799901000010.1074/jbc.M111.314856LouYRybnikerJSalaCColeST2017EspC forms a filamentous structure in the cell envelope of Mycobacterium tuberculosis and impacts ESX-1 secretionMolecular Microbiology103263810.1111/mmi.1357527859904MamanYNir-PazRLouzounY2011Bacteria modulate the CD8+ T cell epitope repertoire of host cytosol-exposed proteins to manipulate the host immune responsePLOS Computational Biology7e100222010.1371/journal.pcbi.100222022022257MillingtonKAFortuneSMLowJGarcesAHingley-WilsonSMWickremasingheMKonOMLalvaniA2011Rv3615c is a highly immunodominant RD1 (region of difference 1) -dependent secreted antigen specific for Mycobacterium tuberculosis infectionPNAS1085730573510.1073/pnas.101515310821427227MittalESkowyraMLUwaseGTinaztepeEMehraAKösterSHansonPIPhilipsJA2018Mycobacterium tuberculosis type VII secretion system effectors differentially impact the ESCRT endomembrane damage responseMBio9e01765-1810.1128/mBio.01765-1830482832NairSRamaswamyPAGhoshSJoshiDCPathakNSiddiquiISharmaPHasnainSEMandeSCMukhopadhyayS2009The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophageThe Journal of Immunology1836269628110.4049/jimmunol.0901367Perez-RiverolYBaiJBandlaCGarcía-SeisdedosDHewapathiranaSKamatchinathanSKunduDJPrakashAFrericks-ZipperAEisenacherMWalzerMWangSBrazmaAVizcaínoJA2022The pride database resources in 2022: a hub for mass spectrometry-based proteomics evidencesNucleic Acids Research50D543D55210.1093/nar/gkab103834723319PymASBrodinPBroschRHuerreMColeST2002Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microtiMolecular Microbiology4670971710.1046/j.1365-2958.2002.03237.x12410828PymASBrodinPMajlessiLBroschRDemangelCWilliamsAGriffithsKEMarchalGLeclercCColeST2003Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosisNature Medicine953353910.1038/nm85912692540ReynissonBAlvarezBPaulSPetersBNielsenM2020NetMHCpan-4.1 and netmhciipan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand dataNucleic Acids Research48W449W45410.1093/nar/gkaa37932406916RoyAEisenhutMHarrisRJRodriguesLCSridharSHabermannSSnellLMangtaniPAdetifaILalvaniAAbubakarI2014Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysisBMJ349g464310.1136/bmj.g464325097193SaelensJWSweeneyMIViswanathanGXet-MullAMJurcic SmithKLSiskDMHuDDCroninRMHughesEJBrewerWJCoersJChampionMMChampionPALoweCBSmithCMLeeSStoutJETobinDM2022An ancestral mycobacterial effector promotes dissemination of infectionCell1854507452510.1016/j.cell.2022.10.01936356582SampsonSLLukeyPWarrenRMvan HeldenPDRichardsonMEverettMJ2001Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917cTuberculosis8130531710.1054/tube.2001.0304SchubertOTLudwigCKogadeevaMZimmermannMRosenbergerGGengenbacherMGilletLCCollinsBCRöstHLKaufmannSHESauerUAebersoldR2015Absolute proteome composition and dynamics during dormancy and resuscitation of Mycobacterium tuberculosisCell Host & Microbe189610810.1016/j.chom.2015.06.00126094805ShahSCannonJRFenselauCBrikenV2015A duplicated ESAT-6 region of ESX-5 is involved in protein export and virulence of mycobacteriaInfection and Immunity834349436110.1128/IAI.00827-1526303392ShahSBrikenV2016Modular organization of the ESX-5 secretion system in Mycobacterium tuberculosisFrontiers in Cellular and Infection Microbiology64910.3389/fcimb.2016.0004927200304ShenHMillerJFFanXKolwyckDAhmedRHartyJT1998Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunityCell9253554510.1016/s0092-8674(00)80946-09491894ShenLSigalLJBoesMRockKL2004Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivoImmunity2115516510.1016/j.immuni.2004.07.00415308097SiegristMSUnnikrishnanMMcConnellMJBorowskyMChengTYSiddiqiNFortuneSMMoodyDBRubinEJ2009Mycobacterial ESX-3 is required for mycobactin-mediated iron acquisitionPNAS106187921879710.1073/pnas.090058910619846780SimeoneRBobardALippmannJBitterWMajlessiLBroschREnningaJ2012Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell deathPLOS Pathogens8e100250710.1371/journal.ppat.100250722319448SolansLAguilóNSamperSPawlikAFriguiWMartínCBroschRGonzalo-AsensioJ2014A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whib6 as a novel ESX-1 componentInfection and Immunity823446345610.1128/IAI.01824-1424891105StanleySARaghavanSHwangWWCoxJS2003Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion systemPNAS100130011300610.1073/pnas.223559310014557536StanleySAJohndrowJEManzanilloPCoxJS2007The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesisJournal of Immunology1783143315210.4049/jimmunol.178.5.314317312162StopferLEMesfinJMJoughinBALauffenburgerDAWhiteFM2020Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibitionNature Communications11276010.1038/s41467-020-16588-932488085StopferLEFlowerCTGajadharASPatelBGallienSLopez-FerrerDWhiteFM2021aHigh-Density, targeted monitoring of tyrosine phosphorylation reveals activated signaling networks in human tumorsCancer Research812495250910.1158/0008-5472.CAN-20-380433509940StopferLEGajadharASPatelBGallienSFrederickDTBolandGMSullivanRJWhiteFM2021bAbsolute quantification of tumor antigens using embedded MHC-I isotopologue calibrantsPNAS118e211117311810.1073/pnas.211117311834497125SuHZhangZLiuZPengBKongCWangHZhangZXuY2018Mycobacterium tuberculosis PPE60 antigen drives Th1/Th17 responses via Toll-like receptor 2–dependent maturation of dendritic cellsJournal of Biological Chemistry293102871030210.1074/jbc.RA118.001696TeufelFAlmagro ArmenterosJJJohansenARGíslasonMHPihlSITsirigosKDWintherOBrunakSvon HeijneGNielsenH2022SignalP 6.0 predicts all five types of signal peptides using protein language modelsNature Biotechnology401023102510.1038/s41587-021-01156-334980915TufarielloJMChapmanJRKerantzasCAWongKWVilchèzeCJonesCMColeLETinaztepeEThompsonVFenyöDNiederweisMUeberheideBPhilipsJAJacobsWR2016Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulencePNAS113E348E35710.1073/pnas.152332111326729876TullyGKortsikCHöhnHZehbeIHitzlerWENeukirchCFreitagKKayserKMaeurerMJ2005Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infectionJournal of Immunology1742174218410.4049/jimmunol.174.4.217415699149UplekarSHeymBFriocourtVRougemontJColeSTFlynnJL2011Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variationInfection and Immunity794042404910.1128/IAI.05344-11van der WelNHavaDHoubenDFluitsmaDvan ZonMPiersonJBrennerMPetersPJ2007M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cellsCell1291287129810.1016/j.cell.2007.05.05917604718WangQBoshoffHIMHarrisonJRRayPCGreenSRWyattPGBarryCEIII2020PE/PPE proteins mediate nutrient transport across the outer membrane of Mycobacterium tuberculosisScience3671147115110.1126/science.aav5912WatsonROManzanilloPSCoxJS2012Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathwayCell15080381510.1016/j.cell.2012.06.04022901810WoodworthJSFortuneSMBeharSM2008aBacterial protein secretion is required for priming of CD8+ T cells specific for the Mycobacterium tuberculosis antigen CFP10Infection and Immunity764199420510.1128/IAI.00307-0818591224WoodworthJSWuYBeharSM2008bMycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivoJournal of Immunology1818595860310.4049/jimmunol.181.12.859519050279World Health Organization 20222021Global tuberculosis report1.1.1World Health OrganizationYangJDMottDSutiwisesakRLuYJRasoFStowellBBabunovicGHLeeJCarpenterSMWaySSFortuneSMBeharSM2018Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophagesPLOS Pathogens14e100706010.1371/journal.ppat.100706029782535YorkIABhutaniNZendzianSGoldbergALRockKL2006Tripeptidyl peptidase II is the major peptidase needed to TRIM long antigenic precursors, but is not required for most MHC class I antigen presentationJournal of Immunology1771434144310.4049/jimmunol.177.3.143416849449ZhengYTShahnazariSBrechALamarkTJohansenTBrumellJH2009The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathwayJournal of Immunology1835909591610.4049/jimmunol.09004411981221110.7554/eLife.84070.sa0Editor's evaluationKanaBavesh DReviewing Editorhttps://ror.org/03rp50x72University of the WitwatersrandSouth Africa
This landmark study uses compelling approaches such as quantitative and screening mass spectrometry to identify peptides from tuberculosis bacteria that are presented by macrophages infected with this pathogen. The authors provide convincing evidence that the presentation of these antigens depends on a specialist bacterial secretion system. The study will be of interest to infectious disease specialists and of particular value for future vaccine development.
10.7554/eLife.84070.sa1Decision letterKanaBavesh DReviewing Editorhttps://ror.org/03rp50x72University of the WitwatersrandSouth Africa
Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.
Decision letter after peer review:
Thank you for submitting your article "Immunopeptidomics reveals determinants of Mycobacterium tuberculosis antigen presentation on MHC class I" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Bavesh Kana as the Senior Editor. The reviewers have opted to remain anonymous.
The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.
Essential revisions:
1. Could the authors speculate why certain antigens (e.g. Rv0288, Rv1886c) that were previously found to be HLA*A2 restricted and elicit abundant Class-I restricted CD8 T cell responses in humans (Axelsson-Robertson, Int J Inf Dis, 2015), were not found to be presented by infected macrophages in this study? It would be useful to cite and discuss this point.
2. Although the authors used macrophages from donors expressing HLA-B*57:01 and HLA-A*02:01, other HLA alleles are expressed on these macrophages. Furthermore, other Mtb peptides were also likely to be presented (such as the PE-PPE proteins, those associated with the mycobacterial outer membrane, or sec substrate TB8.4 mentioned in lines 318-320). Were other peptides found in these quantitative MS experiments? How did their repertoire compare to those found in the initial experiments (even though the focus was on quantifying the 2 peptides mentioned)? If data are available, they would strengthen the results, if not, this should be discussed.
Related: Were peptides other than the 2 that were quantified affected by the Esx1 deletion mutant? (ie non-ESX proteins)
3. Bafilomycin and E64D appear to increase the relative abundance of both the Mtb peptides and other self-peptides. Does the use of these agents also correlate with a shift in MHC-I vs. MHC-II expression on the cell surface? Perhaps related to the mass effect if the Class-II pathway is stalled due to impaired phagolysosomal fusion.
4. If the peptides presented on MHC-I are not affected by proteasome or cathepsin B inhibition, it would be helpful if the authors could discuss why that is the case and which processes are likely responsible for antigen processing in this case (in addition to what is written in lines 252-255).
5. There are a few limitations of this study that should be addressed in the discussion. First, please address in the text why H37Rv was chosen- this is a virulent lab strain but perhaps not the best choice, as it is known to be less virulent than other strains like Erdman, CDC1551 or the Beijing strains. Adding something about this choice and why it might be a limitation of the study would be worth the author's time. Second, the suggestion that ESX-1 is required for the presentation of the antigens from other ESX systems is based on the quantification of two peptides (one from ESX-1 and one from Esx3/5). This may be a limitation of the current study. If it is not, please discuss.
Other points that should be addressed:
1. The authors should mention the rationale/significance of infecting the macrophages for 72h (rather than 24-48h) in the first set of immunopeptidomics experiments. Mtb infection >48h has been associated with the downregulation of MHC-II in infected cells.
2. Hypotheses 1 and 2 are presented in the opposite order in the text (lines 133-134) as in Figure 2a.
3. Citation for the statement in line 292
4. It would be helpful if the rationale for (and the difference between) the Esx5 peptides QTVEDEARRMW vs. QTVEDEARRM(ox)W were mentioned in the Results section in addition to the legend for Figure 3. I had to search to understand why only 2 peptides were mentioned in the text, but data for 3 peptides were shown in the figure.
5. MG-132 increased the expression of extracellular and endosomal peptides, but reduced Mtb and nuclear/cytosolic proteins, which is internally consistent and strengthens the authors' conclusions that the inhibitor worked, but did not affect the expression of the two Mtb peptides quantified.
6. It is unclear why the authors think that Rv1211 and Rv3196A are candidates for proteins that facilitate protein transport across the phagosomal membrane. This seems to be speculation and completely unsupported. (lines 312)
7. There are a few typos in the figure legends (sometimes panels are bolded, and sometimes they are not), and sometimes the order of the figure doesn't align with the figure legends.
8. The manuscript is lacking many of the key citations required to put this work into context. To strengthen this study, the authors should review, cite and discuss their work in the context of the following citations, to provide a clear understanding of what this study adds, and how this study moves the field forward.
Some of the references for the Type VII systems need to be altered. None of the references are the first report of the secretion systems. For ESX-1 please cite PMID: 14557536, for Esx-5 please cite PMID: 17076665, and for ESX-3 please cite PMID: 19846780. (lines 92-96)
The references for cytoplasmic access need revision. Lines 140-121; Please cite PMID: 17604718, for cytoplasmic access; PMID: 22319448, as well as Watson 2012 for ESX-1 dependency.
The authors need to consider the following references regarding ESX-1 and MHC presentation: PMID: 22022257, which suggests that access to the cytoplasm is required for MHC type 1 presentation in M. tuberculosis; PMID: 18591224, which shows that ESX-1 function is required for priming CD8 T cells, and presenting EsxB peptides, also found here. PMID: 19360129, defining the pathway used by MHC during M. tb infection for phagosomal antigens, PMID: 22901810, showed ESX-1 dependent localization of p62; It is already known that MTb localizes with markers of phagosomal membrane damage in an ESX-1 dependent manner.
The authors should consider these references demonstrating that BCG lacks ESX-1 activity (lines 288-290) References demonstrating BCG is attenuated because it lacks ESX-1: PMID: 10320585, BCG is missing RD1, PMID: 12410828 RD1 contributes to BCG attenuation, PMID: 12508154 deletion of RD1 from TB leads to attenuation, PMID: 12692540 restoring ESAT-6 secretion to BCG.
The authors should review these references (lines 300-302) first suggesting the model that the ESX-1 function precedes that of the other ESX systems (2-5). PMID: 33653883 first suggested that ESX-1 functions to lyse the phagosome, and that ESX-1 activity is followed by the activity of the other ESX secretion systems (see the final model in this paper). ESX-3 was first shown to function downstream of ESX-1 in this paper (PMID: 30482832).
The original papers reporting these proteins are secreted/ localized should be cited. PMID: 19682254 EspC was first reported as an ESX substrate here. For the list of proteins in 318-320. Please address the rest.
In lines 308-315, did the authors check if other papers that have defined the ESX-1 secretome have seen these proteins? Check PMID: 35671426 for the M. marinum orthologs.
Reviewer #1 (Recommendations for the authors):
The inclusion of T-cell activation experiments to validate the immunogenicity of some of the peptides would enhance the manuscript.
Reviewer #2 (Recommendations for the authors):
This is a very nice study. Overall, it is clever and well-presented and adds to the knowledge in the field. The approaches are rigorous, and the identification of mycobacterial peptides in the background of the host peptides is impressive. The conclusions are supported by the data presented. The figures and description of the methods are clear and transparent and will allow the field to reproduce this work. The authors could improve this manuscript by considering the points below. A major issue with the manuscript is that the references need to be reconsidered and improved. The study needs to be put into a clear context of the MHC, and ESX fields. We hope that this list of suggested references below will provide the authors with a means to do so.
The manuscript is lacking many of the key citations required to put this work into context. To strengthen this study, the authors should review, cite and discuss their work in the context of the following citations, to provide a clear understanding of what this study adds, and how this study moves the field forward.
Some of the references for the Type VII systems need to be altered. None of the references are the first report of the secretion systems. For ESX-1 please cite PMID: 14557536, for Esx-5 please cite PMID: 17076665, and for ESX-3 please cite PMID: 19846780. (lines 92-96)
The references for cytoplasmic access need revision. Lines 140-121; Please cite PMID: 17604718, for cytoplasmic access; PMID: 22319448, as well as Watson 2012 for ESX-1 dependency.
The authors need to consider the following references regarding ESX-1 and MHC presentation: PMID: 22022257, which suggests that access to the cytoplasm is required for MHC type 1 presentation in M. tuberculosis; PMID: 18591224, which shows that ESX-1 function is required for priming CD8 T cells, and presenting EsxB peptides, also found here. PMID: 19360129, defining the pathway used by MHC during M. tb infection for phagosomal antigens, PMID: 22901810, showed ESX-1 dependent localization of p62; It is already known that MTb localizes with markers of phagosomal membrane damage in an ESX-1 dependent manner.
The authors should consider these references demonstrating that BCG lacks ESX-1 activity (lines 288-290) References demonstrating BCG is attenuated because it lacks ESX-1: PMID: 10320585, BCG is missing RD1, PMID: 12410828 RD1 contributes to BCG attenuation, PMID: 12508154 deletion of RD1 from TB leads to attenuation, PMID: 12692540 restoring ESAT-6 secretion to BCG.
The authors should review these references (lines 300-302) first suggesting the model that the ESX-1 function precedes that of the other ESX systems (2-5). PMID: 33653883 first suggested that ESX-1 functions to lyse the phagosome, and that ESX-1 activity is followed by the activity of the other ESX secretion systems (see the final model in this paper). ESX-3 was first shown to function downstream of ESX-1 in this paper (PMID: 30482832)
The original papers reporting these proteins are secreted/ localized should be cited. PMID: 19682254 EspC was first reported as an ESX substrate here. For the list of proteins in 318-320. Please address the rest.
In lines 308-315, did the authors check if other papers that have defined the ESX-1 secretome have seen these proteins? Check PMID: 35671426 for the M. marinum orthologs.
It is unclear why the authors think that Rv1211 and Rv3196A are candidates for proteins that facilitate protein transport across the phagosomal membrane. This seems to be speculation and completely unsupported. (lines 312)
There are a few limitations of this study that should be addressed in the discussion. First, please address in the text why H37Rv was chosen- this is a virulent lab strain but perhaps not the best choice, as it is known to be less virulent than other strains like Erdman, CDC1551 or the Beijing strains. This is not an issue for this reviewer but I suspect adding something about this choice and why it might be a limitation of the study would be worth the author's time. Second, the suggestion that ESX-1 is required for the presentation of the antigens from other ESX systems is based on the quantification of two peptides (one from ESX-1 and one from Esx3/5). This may be a limitation of the current study. If it is not, please discuss this in the discussion.
There are a few typos in the figure legends (sometimes panels are bolded, and sometimes they are not), and sometimes the order of the figure doesn't align with the figure legends.
Reviewer #3 (Recommendations for the authors):
– Could the authors speculate why certain antigens (e.g. Rv0288, Rv1886c) that were previously found to be HLA*A2 restricted and elicit abundant Class-I restricted CD8 T cell responses in humans (Axelsson-Robertson, Int J Inf Dis, 2015), were not found to be presented by infected macrophages in this study? It would be useful to cite and discuss this point.
– Although the authors used macrophages from donors expressing HLA-B*57:01 and HLA-A*02:01, other HLA alleles are expressed on these macrophages. Furthermore, other Mtb peptides were also likely to be presented (such as the PE-PPE proteins, those associated with the mycobacterial outer membrane, or sec substrate TB8.4 mentioned in lines 318-320). Were other peptides found in these quantitative MS experiments? How did their repertoire compare to those found in the initial experiments (even though the focus was on quantifying the 2 peptides mentioned)? If data are available they would strengthen the results, but at least could be discussed.
Related: Were peptides other than the 2 that were quantified affected by the Esx1 deletion mutant? (ie non-ESX proteins)
– Bafilomycin and E64D appear to increase the relative abundance of both the Mtb peptides and other self-peptides. Does the use of these agents also correlate with a shift in MHC-I vs. MHC-II expression on the cell surface? Perhaps related to the mass effect if the Class-II pathway is stalled due to impaired phagolysosomal fusion.
– If the peptides presented on MHC-I are not affected by proteasome or cathepsin B inhibition, it would be helpful if the authors could discuss in the Discussion why that is the case and which processes are likely responsible for antigen processing in this case (in addition to what is written in lines 252-255).
10.7554/eLife.84070.sa2Author response
Essential revisions:
1. Could the authors speculate why certain antigens (e.g. Rv0288, Rv1886c) that were previously found to be HLA*A2 restricted and elicit abundant Class-I restricted CD8 T cell responses in humans (Axelsson-Robertson, Int J Inf Dis, 2015), were not found to be presented by infected macrophages in this study? It would be useful to cite and discuss this point.
This is an important point, and we appreciate the reviewers bringing it up. In general, while identifying a peptide in the MHC-I repertoire by MS provides strong positive evidence for its presentation, the fact that a given epitope was not detected in our MS analyses should not be interpreted as conclusive evidence that it cannot be presented on MHC-I in Mtb infection. We’ve made an effort to emphasize that there are several reasons why previously described T cell epitopes may not have been detected in our MS analyses:
1. Other types of APCs besides macrophages can also become infected with Mtb or otherwise take up Mtb antigen and prime CD8+ T cells during Mtb infection. If other cell types such as dendritic cells differ in the antigen processing proteases or antigen presentation pathways they express, they may present different sets of epitopes that could prime T cell responses such as those observed by Axelsson-Robertson et al. that are specific for epitopes we did not detect.
2. Depending on their physical and chemical properties, some MHC-I peptides may be partially or completely lost during sample handling (for example, very hydrophobic peptides may be retained on the C18 SPE column – see PMID: 36194871), or may not ionize efficiently and therefore produce an MS signal below the limit of detection.
3. DDA MS analyses are inherently stochastic (as the instrument makes real-time decisions in each analysis about which MS peaks to select for fragmentation) and. MHC-I peptides that were not picked for fragmentation, either due to lower abundance compared to other simultaneously eluting peptides, or by chance, will not be identified.
We’ve added a summary of these possible reasons to the discussion text (lines 432-447):
“We did not detect any peptides derived from several antigens previously shown to stimulate CD8+ T cell responses in Mtb infection, including responses restricted to HLA alleles represented in our DDA MS analyses [for example, EsxH and FbpB (Axelsson-Robertson et al., 2015)]. This could be due to any of several biological and/or technical reasons. Given that the Mtb-derived MHC-I peptides we detected were enriched for T7SS substrates but not for substrates of the Sec or Tat secretion pathways, it’s possible that the subcellular localization of antigens secreted via these pathways does not enable efficient presentation on MHC-I in macrophages. In this case, other types of APCs that differ in their antigen processing and presentation capabilities could still present peptides from these antigens to prime the previously observed CD8+ T cell responses. The same could also be true of certain T7SS substrate antigens (such as EsxH) if T7SS substrates vary in their subcellular localization or if presentation of certain epitopes requires antigen processing pathways not active in macrophages. Some peptides may also have been missed because they were lost during sample handling, because they were below the limit of detection due to low abundance or ionization efficiency, or because they co-eluted with many more abundant peptides and were therefore not prioritized for acquisition in DDA analyses. Our results don’t rule out presentation of additional antigens besides those we detected.”
2. Although the authors used macrophages from donors expressing HLA-B*57:01 and HLA-A*02:01, other HLA alleles are expressed on these macrophages. Furthermore, other Mtb peptides were also likely to be presented (such as the PE-PPE proteins, those associated with the mycobacterial outer membrane, or sec substrate TB8.4 mentioned in lines 318-320). Were other peptides found in these quantitative MS experiments? How did their repertoire compare to those found in the initial experiments (even though the focus was on quantifying the 2 peptides mentioned)? If data are available, they would strengthen the results, if not, this should be discussed.
Related: Were peptides other than the 2 that were quantified affected by the Esx1 deletion mutant? (ie non-ESX proteins)
We thank the reviewers for pointing out a lack of clarity in the manuscript about the nature of the data we get out of our targeted quantitative MS analyses. We’ve attempted to clarify that these analyses only target the specific peptides for which we spike in corresponding stable isotope labeled (SIL) synthetic standards – specifically LLDEGKQSL (from EsxA), QTVEDEARRMW (from EsxJKPW) and, in the drug treatment experiments in Figure 4, several self peptides. Detection of the synthetic standard triggers acquisition of the biological peptide, so other peptides are not detected. Given that the primary cells used for these quantitative experiments were chosen such that all three donors expressed HLA-A*02:01 and HLA-B*57:01 but did not have any other HLA alleles in common, none of the other peptides we identified would have been detectable in cells from all three donors, even if corresponding SIL standards had been added. It’s unlikely that we would have been able to readily obtain cells from three or more donors all sharing three or more HLA of the relevant alleles.
We also emphasize the advantages of this approach that we feel compensate for the narrow focus on only a few peptides, including reliable acquisition across experimental conditions and the low limit of detection, which decreases the required sample input and makes experiments with many experimental conditions tractable.
We introduce these points in lines 202-205, which now read as follows: “Because the other Mtb epitopes detected in our untargeted MS experiments are not expected to bind these HLA alleles, we only targeted EsxA28-36 and EsxJKPW24-34. While this targeted approach is limited in the number of epitopes it can detect, it enables reliable and accurate quantification of peptides across experimental conditions with low sample input.”
3. Bafilomycin and E64D appear to increase the relative abundance of both the Mtb peptides and other self-peptides. Does the use of these agents also correlate with a shift in MHC-I vs. MHC-II expression on the cell surface? Perhaps related to the mass effect if the Class-II pathway is stalled due to impaired phagolysosomal fusion.
The reviewer raises an interesting hypothesis that we hadn’t previously considered. To determine whether a tradeoff between antigen presentation on MHC-I vs. MHC-II could lead to an increase in presentation of certain MHC-I epitopes in response to E64d or bafilomycin treatment, we analyzed flow cytometry data we had previously collected measuring surface MHC-I levels in Mtb-infected macrophages treated with these drugs, and also stained Mtb-infected macrophages treated with E64d or bafilomycin for surface HLA-DR and HLA-DQ. We found that treatment with E64d led to a slight and not statistically significant decrease in MHC-I and MHC-II expression while the effect of bafilomycin treatment on MHC-I and MHC-II surface levels was minimal. This led us to conclude that a tradeoff between directing antigen to MHC-I vs. MHC-II processing pathways was unlikely to be a major contributor to the effects of drug treatment that we observed in our targeted MS experiments. To present these data, we’ve extended Figure 4 —figure supplement 3 to include two additional panels D and E that present the MHC-I data, and added Figure 4 —figure supplement 4 to present the MHC-II data.
We describe the results of our analysis of surface MHC-I on drug-treated cells on lines 272-275, which now read “All three drugs exhibited minimal cytotoxicity in macrophages at the doses used in our immunopeptidomic experiments (Figure 4 —figure supplement 2), and did not inhibit phagocytosis of Mtb or bacterial outgrowth (Figure 4 —figure supplement 3), and did not have a significant effect on surface MHC-I levels (Figure 4 —figure supplement 3).”
We describe the results of our analysis of surface MHC-II on E64d and bafilomycin-treated cells on lines 284-288, which read: “Cell surface levels of HLA-DR and HLA-DQ were not significantly affected by bafilomycin or E64d treatment (Figure 4 —figure supplement 4), suggesting that E64d and bafilomycin did not substantially stall MHC-II antigen presentation and their effects of on MHC-I presentation could not be explained as indirect effects of modulating antigen entry into the MHC-II antigen processing pathway.”
We’ve amended the Methods subsection on flow cytometry to include a description of the MHC-II-specific antibodies used (lines 743-752).
4. If the peptides presented on MHC-I are not affected by proteasome or cathepsin B inhibition, it would be helpful if the authors could discuss why that is the case and which processes are likely responsible for antigen processing in this case (in addition to what is written in lines 252-255).
We appreciate the reviewer’s interest in possible alternative pathways of antigen processing, and we are eager to explore these possibilities in future work. We have added a paragraph to the discussion outlining some possible alternative proteolytic pathways that have previously been proposed to contribute to antigen processing on MHCs that could be involved in processing Mtb antigens presented on MHC-I (lines 379-389).
“We showed that presentation of two Mtb-derived peptides on MHC-I was independent of the activity of proteases commonly associated with antigen processing (the proteasome and cysteine cathepsins), suggesting an alternate processing mechanism. Other proteases have previously been proposed to contribute to proteolytic processing of antigens for presentation on MHCs, including tripeptidyl peptidase II (Geier et al., 1999; Guil et al., 2006; Lázaro et al., 2015; York et al., 2006), nardilysin (Kessler et al., 2011), thimet oligopeptidase (Kessler et al., 2011), metalloproteinases (Lorente et al., 2012), and serine cathepsins such as Cathepsin G that are not inhibited by E64d (Burster et al., 2010). Some of these or other enzymes may be responsible for proteolytic processing of EsxA28-36 and EsxJKPW24-34, or may have a redundant role that can compensate for inhibition of conventional antigen processing pathways. Further work will be needed to determine which proteolytic pathways contribute to presentation of Mtb T7SS substrates on MHC-I.”
5. There are a few limitations of this study that should be addressed in the discussion. First, please address in the text why H37Rv was chosen- this is a virulent lab strain but perhaps not the best choice, as it is known to be less virulent than other strains like Erdman, CDC1551 or the Beijing strains. Adding something about this choice and why it might be a limitation of the study would be worth the author's time. Second, the suggestion that ESX-1 is required for the presentation of the antigens from other ESX systems is based on the quantification of two peptides (one from ESX-1 and one from Esx3/5). This may be a limitation of the current study. If it is not, please discuss.
We appreciate the reviewer’s interest in how antigen presentation might vary among Mtb isolates. This is a question we also think will be interesting and important to investigate to understand both the fundamental biology of antigen presentation in TB and how to ensure broad vaccine protection across Mtb strains. We’ve added a paragraph addressing this point to the discussion (lines 372-377), which reads as follows:
“In this study, we used strain H37Rv for the sake of consistency with other prior studies on antigen presentation on MHC-I and phagosome membrane damage in Mtb-infection, but antigen presentation may vary among Mtb isolates. Mtb isolates have been shown to differ in their level of ESX-1 activity (Solans et al., 2014), as well as carrying mutations in Esx-family proteins and other T7SS substrates (Saelens et al., 2022; Uplekar et al., 2011). Further studies across multiple isolates may therefore reveal differences in antigen presentation that could be relevant for the design of broadly protective vaccines.”
Our ability to generalize about the ESX-1-dependence of MHC-I antigen presentation in Mtb infection is indeed limited by the fact that our quantitative experiments targeted two specific epitopes. To clarify this point, we’ve added more language in the discussion acknowledging the possibility that the requirements for antigen presentation on MHC-I may vary among different Mtb antigens. We’ve revised lines 340-343 to read “While ESX-1 activity is required for priming of CD8+ T cell responses specific for EsxB in vivo in mice, it is dispensable for priming of CD8+ T cell responses specific for antigens exported via other secretion systems (such as TB8.4 and EsxH) in vivo in mice (Woodworth et al., 2008a).” to emphasize the possibility of differences among antigens, and added lines 368-370, which read “Given that our quantitative MS experiments only targeted two Mtb-derived epitopes, further experiments will also be needed to determine whether these results extend to all Mtb T7SS substrates or all Mtb MHC-I antigens, or only a subset.”
Other points that should be addressed:
1. The authors should mention the rationale/significance of infecting the macrophages for 72h (rather than 24-48h) in the first set of immunopeptidomics experiments. Mtb infection >48h has been associated with the downregulation of MHC-II in infected cells.
We agree with the reviewer that the time point selected is an important methodological consideration. Based on prior experience in our lab, we knew that infection of hMDMs with Mtb at MOI 2-3 for >72 hours would result in a high rate of cell death, whereas cell viability is high at 72 hours. We did not want to select an earlier time point because antigens transiently presented early in infection might not be protective if T cell responses take multiple days to initiate. Also, we show in Figure 3 —figure supplement 1 that infection with H37Rv does not result in down-regulation of surface MHC-I at 72 hours, which led us to conclude that global down-regulation of MHC-I antigen presentation was not a concern when analyzing antigen presentation in Mtb-infected hMDMs at that time point.
We’ve added the following on lines 62-66 to clarify our rationale: “We selected the 72 hour time point over shorter time points because it has previously been reported that some Mtb antigens are expressed only transiently, early in infection (Moguche et al., 2017), whereas Mtb-specific T cell responses may take multiple days to initiate, either upon priming (Chackerian et al., 2002) or during a recall response (Gallegos et al., 2008). Past experience suggested that choosing a longer time point would have resulted in a high rate of cell death.”
2. Hypotheses 1 and 2 are presented in the opposite order in the text (lines 133-134) as in Figure 2a.
We apologize for the oversight. Thanks to the reviewer for pointing this out! We’ve changed the order in which the hypotheses are presented in the text. Lines 140-141 now read “(1) be processed by endolysosomal proteases and loaded onto MHC-I in Mtb-containing compartments, or (2) gain access to cytosolic antigen processing pathways via permeabilization of the phagosome membrane (Grotzke et al., 2010, 2009; van der Wel et al., 2007).”
3. Citation for the statement in line 292
The prior research this statement refers to is described in more detail in the next few sentences and cited there, but we’ve added the appropriate citations to this line (now line 337) as well for the sake of clarity. Thanks to the reviewer for pointing out the ambiguity.
4. It would be helpful if the rationale for (and the difference between) the Esx5 peptides QTVEDEARRMW vs. QTVEDEARRM(ox)W were mentioned in the Results section in addition to the legend for Figure 3. I had to search to understand why only 2 peptides were mentioned in the text, but data for 3 peptides were shown in the figure.
We appreciate the reviewer pointing out this lack of clarity. In lines 205-207 of the text, we added a sentence explaining the rationale for targeting both the oxidized and non-oxidized form of the peptide: “Because methionine residues of peptides can oxidize during sample handling, we targeted both the oxidized and non-oxidized form of EsxJKPW24-34 where possible.”
5. MG-132 increased the expression of extracellular and endosomal peptides, but reduced Mtb and nuclear/cytosolic proteins, which is internally consistent and strengthens the authors' conclusions that the inhibitor worked, but did not affect the expression of the two Mtb peptides quantified.
We thank the reviewer for this observation. We agree that the effect of MG-132 on peptides derived from cytosolic and nuclear proteins supports our conclusion that the inhibitor worked, even though we did not see the expected effect on Mtb peptides. This was the basis for our conclusion that processing of the Mtb peptides quantified in this experiment does not require the proteasome.
6. It is unclear why the authors think that Rv1211 and Rv3196A are candidates for proteins that facilitate protein transport across the phagosomal membrane. This seems to be speculation and completely unsupported. (lines 312)
We apologize for the lack of clarity in this passage and thank the reviewer for pointing out that our wording here was ambiguous. What we meant was not that Rv1211 and Rv3196A might facilitate the transport of other proteins across the phagosome membrane but rather that the fact that Rv1211 and Rv3196A are small, low molecular weight proteins might make it easier for them to diffuse through pores introduced into the phagosome membrane by Mtb. We’ve reworded and attempted to clarify this sentence, which now reads “TB8.4, Rv1211, and Rv3196A are all low molecular weight proteins, which we speculate could make it easier for them to translocate through pores in a permeabilized phagosomal membrane.”
7. There are a few typos in the figure legends (sometimes panels are bolded, and sometimes they are not), and sometimes the order of the figure doesn't align with the figure legends.
We thank the reviewer for pointing out these issues. We’ve done our best to proofread the figure legends again, making sure the letters identifying figure panels are always capitalized and bolded, that typos are corrected, and that the letter indices of figure panels match the caption.
We made the following changes to the figure legends:
– Capitalized and bolded “(C)" in Figure 3 caption (line 236)
– Changed “flow cytometry plots” to “flow cytometry contour plots” in Figure 4 —figure supplement 3A caption
8. The manuscript is lacking many of the key citations required to put this work into context. To strengthen this study, the authors should review, cite and discuss their work in the context of the following citations, to provide a clear understanding of what this study adds, and how this study moves the field forward.
We are grateful to the reviewer for taking the time to point us to so many of these references! More specific comments are in-line below.
Some of the references for the Type VII systems need to be altered. None of the references are the first report of the secretion systems. For ESX-1 please cite PMID: 14557536, for Esx-5 please cite PMID: 17076665, and for ESX-3 please cite PMID: 19846780. (lines 92-96)
These references have been added.
The references for cytoplasmic access need revision. Lines 140-121; Please cite PMID: 17604718, for cytoplasmic access; PMID: 22319448, as well as Watson 2012 for ESX-1 dependency.
These references have been added.
The authors need to consider the following references regarding ESX-1 and MHC presentation: PMID: 22022257, which suggests that access to the cytoplasm is required for MHC type 1 presentation in M. tuberculosis; PMID: 18591224, which shows that ESX-1 function is required for priming CD8 T cells, and presenting EsxB peptides, also found here. PMID: 19360129, defining the pathway used by MHC during M. tb infection for phagosomal antigens, PMID: 22901810, showed ESX-1 dependent localization of p62; It is already known that MTb localizes with markers of phagosomal membrane damage in an ESX-1 dependent manner.
We appreciate the reviewer’s guidance on contextualizing the relationship between ESX-1 function and MHC-I antigen presentation. We’ve added a discussion of how the bioinformatic studies in PMID: 22022257 support the functional relevance of presentation of T7SS substrates on MHC-I on lines 426-430, which read “Bioinformatic studies have also shown that predicted class I HLA-binding motifs are statistically underrepresented in several Esx-family protein sequences, suggesting that these proteins may be under selective pressure to escape recognition by CD8+ T cells (Maman et al., 2011). This finding provides further support for the idea that T cell recognition of T7SS substrates presented on MHC-I is functionally relevant to protective immunity against Mtb infection.”
We’ve added some additional detail and nuance to our discussion of PMID: 18591224 in lines 340-346 to acknowledge that the authors of this paper argue that ESX-1 is dispensable for non-ESX-1 substrates, but required for ESX-1 substrates. These lines now read “While ESX-1 activity is required for priming of CD8+ T cell responses specific for EsxB in vivo in mice, it is dispensable for priming of CD8+ T cell responses specific for antigens exported via other secretion systems (such as TB8.4 and EsxH) (Woodworth et al., 2008a). While these prior results suggest that the requirements for presentation of Mtb antigens on MHC-I may vary among Mtb antigens and/or vary among antigen presenting cell types, our results show that ESX-1 activity is essential for the presentation of certain Mtb antigens in infected human macrophages, beyond ESX-1 substrates alone.”
We’ve also made an effort to highlight prior evidence that cytosolic antigen processing is required for presentation of Mtb antigens on MHC-I in human dendritic cells. Lines 363-366 now read “Prior studies have shown that Mtb antigens must access the cytosol to be presented on MHC-I in human monocyte-derived dendritic cells (Grotzke et al., 2010, 2009; Lewinsohn et al., 2006), and our results are consistent with a model in which ESX-1-mediated phagosomal membrane damage enables Mtb antigens to access cytosolic antigen processing and presentation pathways.”
We’ve expanded on the passage where we highlight prior results showing ESX-1-dependent phagosome membrane damage to emphasize that the purpose of our microscopy experiments was primarily to demonstrate that this phenomenon was occurring in our primary hMDM model system at timepoints relevant to our MS analyses. Lines 159-161 now read “Our results are consistent with prior studies demonstrating that ESX-1 activity is required for Mtb to damage the phagosome membrane (Augenstreich et al., 2017; Simeone et al., 2012; Watson et al., 2012) and show that this phenomenon occurs in our primary human macrophage infection model.”
The authors should consider these references demonstrating that BCG lacks ESX-1 activity (lines 288-290) References demonstrating BCG is attenuated because it lacks ESX-1: PMID: 10320585 , BCG is missing RD1, PMID: 12410828 RD1 contributes to BCG attenuation, PMID: 12508154 deletion of RD1 from TB leads to attenuation, PMID: 12692540 restoring ESAT-6 secretion to BCG.
Thank you to the reviewers for these additional references. The last reference above (PMID: 12692540) suggested a possible implication of our study that we hadn’t explicitly spelled out in our discussion – namely that. In addition to adding the suggested citations, we’ve added the following on lines 332-335: “The absence of ESX-1 in BCG therefore could limit the ability of BCG to prime effective T cell responses against Mtb, not only because of the absence of antigens encoded in the ESX-1 locus but also because of altered or reduced presentation of other antigens (Pym et al., 2003).”
The authors should review these references (lines 300-302) first suggesting the model that the ESX-1 function precedes that of the other ESX systems (2-5). PMID: 33653883 first suggested that ESX-1 functions to lyse the phagosome, and that ESX-1 activity is followed by the activity of the other ESX secretion systems (see the final model in this paper). ESX-3 was first shown to function downstream of ESX-1 in this paper (PMID: 30482832).
These are both excellent precedents to cite. We’ve expanded our discussion of the interdependence of T7SSs in the intracellular setting as follows (lines 346-355): “Whereas in axenic culture, secretion of ESX-5 substrates is independent of ESX-1 function (Champion et al., 2006; Shah and Briken, 2016), the fact that presentation of peptides derived from an ESX-5 substrate on MHC-I requires ESX-1 activity supports the hypothesis that the localization of secreted Mtb proteins within a host cell may depend on the activity of multiple T7SSs. This dependence on multiple T7SSs has previously been shown for other ESX-5 substrates such as CpnT (Izquierdo Lafuente et al., 2021), and a functional interdependence between ESX-1 and ESX-3 (which respectively damage the phagosome membrane and prevent host membrane repair) has previously been proposed (Mittal et al., 2018). Our results suggest that the interdependence of Mtb T7SSs in an intracellular context influences the availability of Mtb antigens for processing and presentation on MHC-I.”
The original papers reporting these proteins are secreted/ localized should be cited. PMID: 19682254 EspC was first reported as an ESX substrate here. For the list of proteins in 318-320. Please address the rest.
We’ve added a citation to PMID: 19682254. We were unable to find any earlier reports of PPE51, PPE60, or PPE20 being localized to the outer membrane than the references already cited and are convinced these are the earliest reports conclusively showing outer membrane localization of these particular PPE proteins. On line 406 we’ve added citations to PMID: 11800581 and PMID: 17076665, which to the best of our knowledge established (respectively) that PE/PPE proteins can be localized to the outer membrane and that this process depends on type VII secretion systems.
In lines 308-315, did the authors check if other papers that have defined the ESX-1 secretome have seen these proteins? Check PMID: 35671426 for the M. marinum orthologs.
We thank the reviewer for this helpful suggestion! M. marinum does not encode a known ortholog of Rv1211, but does encode an ortholog of Rv3196A (MMAR_1367), which is detected in the supernatants of M. marinum in PMID: 35671426 in a non-ESX-1-dependent manner. This is consistent with the idea that Rv3196A could be secreted, albeit not by ESX-1. Accordingly, we’ve added a citation to PMID: 35671426 in lines 392-395, which now read “Rv1211 and Rv3196A have both previously been detected by MS in culture filtrates of Mtb (Bell et al., 2012), as has the Mycobacterium marinum ortholog of Rv3196A (MMAR_1367) (Cronin et al., 2022), suggesting that either or both of these proteins could be secreted despite lacking readily identifiable secretion signals.”